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Abstract 
 
Glutathione S-transferase A3-3 is the most catalytically efficient steroid isomerase enzyme 
known in humans, transforming Δ5-androstene-3-17-dione into Δ4-androstene-3-17-dione. 
Though its mechanism of action remains unsolved. GSTA3-3 catalyses this reaction with at 
least ten-fold greater efficiency than GSTA1-1, its closest competitor in the Alpha class of 
GSTs. In order to examine the differences between Alpha class GSTs and to better elucidate 
the mechanism of GSTA3-3 the roles of Tyr9 and Arg15 were examined. Tyr9 is the major 
catalytic residue of Alpha class GSTs and Arg15 is proposed to be catalytically important to 
GSTA3-3 but never before experimentally examined. While the structure and stability of the 
Alpha class enzymes are highly comparable, subtle differences at the G-site of the enzymes 
account for GSTA3-3 having a ten-fold greater affinity for the substrate GSH. Y9F and R15L 
mutations, singly or together, have no effect on the structure and stability of GSTA3-3 (the 
same effect they have on GSTA1-1) despite the R15L mutation removing an interdomain salt-
bridge at the active site. Hydrogen-deuterium exchange mass spectrometry also revealed that 
neither mutation had a significant effect on the conformational dynamics of GSTA3-3. The 
R15L and Y9F mutations are equally important to the specific activity of the steroid isomerase 
reaction; however, Arg15 is more important for lowering the pKa of GSH. Lowering the pKa 
of GSH being how GSTs catalyse their reactions. This suggests an additional role for Tyr9, 
with an important mechanistic implication.  Factoring in the inability to detect an intermediate 
during the reaction, all data are in agreement with the mechanism being concerted and that 
Tyr9 acts as a proton shuttle. Additionally, there is evidence to suggest that Arg15 is integral 
to allowing GSTA3-3 to differentiate between Δ5-androstene-3-17-dione and Δ4-androstene-3-
17-dione, indicating that Arg15 is a more important active-site residue than previously 
recognized. 
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Chapter 1 
Introduction 
 
1.1. Steroid biosynthesis 
 
As a natural response to environmental pressures, evolution has over millennia resulted in the 
refinement of complex biological systems to improve their functionality and adaptability. 
Biological systems exist as a complex network of thousands of organic and inorganic 
compounds interacting to maintain homeostasis and/or to signal and carry out metabolism, 
growth and adaption.  
 
Steroids are one such class of organic compounds participating in this complex network (Figure 
1). Steroids have two primary functions: certain steroids (e.g. cholesterol) are important 
components of cell membranes which govern membrane fluidity1 while other steroids (e.g. 
testosterone) act as signalling molecules which activate steroid hormone receptors.2 Through 
these two functions steroids play important roles in regulating metabolic pathways, stress 
reactions, salt balance and sexual development. Steroids are common in almost all eukaryotic 
cells, including those of humans, animals, plants, fungi and insects.  
 
Helping to regulate the complex network of organic compounds, including steroids, that life 
depends on are a different class of organic macromolecules called enzymes. Enzymes have 
evolved as powerful biological catalysts that have been optimised to allow a more efficient 
flow of energy and material through biological systems.3,4  As catalysts, they act to reduce the 
activation energy of chemical reactions, making them indispensable to the proper metabolism 
of biological systems. The regulation of enzymes by activators, inhibitors, post-translational 
modifications and quantity in turn, therefore, controls metabolism.  The regulation of enzymes 
can be carried out by positive or negative feedback loops as well as cell signalling molecules 
such as steroids.  
 
The complex relationship between steroids and enzymes is a microcosm of the intricate 
relationship between the network of organic and inorganic compounds that create biological 
2 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: The steroid core structure. The core structure is composed of seventeen carbon atoms 
(numbered 1-17), bonded in four fused rings: three six-member cyclohexane rings (rings A, B and 
C) and one five-membered cyclopentane ring (ring D).5 Carbon atoms 18 and above are not always 
present. Steroids vary by the functional groups attached to this four-ring core and by the oxidation state 
of the rings. Ketosteroids are forms of steroids with a ketone group, usually at positions 3 and/or 17. 
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systems in general but also serves to highlight the interconnectivity and dependence of the two 
classes of compounds on each other. 
 
The production of steroid hormones such as testosterone and progesterone from cholesterol 
(itself the product of a complex metabolic pathway beginning with the mevalonate pathway6) 
proceeds via a complex series of oxidation and isomerisation reactions (Figure 2).7 A critical 
step in the metabolic pathway is the isomerisation of the double bond of androst-5-ene-3,17-
dione (Δ5-AD) to the androst-4-ene-3,17-dione (Δ4-AD) isomer. In bacteria, this isomerisation 
reaction is carried out by α-ketosteroid isomerase (KSI)8,9 while in mammalian tissue the 
reaction is carried out by the close homologue glutathione S-transferase (GST) A3-3.10-12 
Although the reaction mechanism of bacterial KSI has been elucidated8 the reaction mechanism 
of GSTA3-3 (the primary enzyme of interest to this study) remains indeterminate.  
 
This introduction will demonstrate that a GST enzyme being responsible for the control and 
synthesis of steroid production is unusual and inconsistent with the typical function of the 
enzyme.  Understanding the nature of this new function in GSTs is important, not only to 
understand an important biological process in humans, but to elucidate further the relationship 
between structure and function in proteins.  
 
1.2. Glutathione S-transferase superfamily 
 
The GST enzymes (EC 2.5.1.18) constitute a large and ancient protein superfamily of phase II 
detoxification enzymes best known for their ability to catalyse the conjugation of the reduced 
form of glutathione (γ-glutamylcysteinylglycine, GSH) to a wide variety of endogenous and 
exogenous compounds. The superfamily is, in turn, subdivided into three smaller protein 
families: the cytosolic, mitochondrial and microsomal GSTs.13,14  The cytosolic GSTs (of 
interest to this study) are then further categorised into over 12 classes [structural classification 
of proteins (SCOP)].15 GST enzymes are found in almost all aerobic organisms including 
bacteria, yeasts, plants, insects and vertebrates.16 They are absent only in the Archaea domain 
which almost universally does not even produce the substrate of the enzyme.17 
                                                          
 http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.b.gb.b.b.html 
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Figure 2: The biosynthesis of steroid hormones from cholesterol. Other hormones are produced 
from cholesterol or downstream products but have not been shown as they are outside the scope of this 
study. The role of KSI and GSTA3-3 in catalysing the formation of Δ4-androstene-3,17-dione (which 
may subsequently be transformed into testosterone) and Δ4-pregnene-3,20-dione is shown.7  
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1.2.1. Classification of the glutathione S-transferase enzymes 
 
The cytosolic GSTs are categorised into classes according to a variety of factors including their 
sequence identity, structure, substrate specificity and immunological reactions.14 The 
mammalian GSTs are grouped into nine species-independent gene classes designated by the 
names of Greek letters: Alpha, Mu, Pi,18 Sigma,19 Theta,20 Kappa,21 Zeta,22 Beta23 and 
Omega.24  Additionally, there are classes of cytosolic GSTs unique to insects (Delta)25 and 
plants (Phi and Tau).26 Lastly, there are GST classes unique to and named for their organism 
of origin such as Plasmodium falciparum27 and Schistosoma.28 
 
GSTs are also classified according to their species of origin and the makeup of their dimeric 
structure. The large number of GST proteins; which must be identified by species of origin, 
class and the makeup of their subunits has necessitated the development of a precise GST 
nomenclature (Figure 3).29  
 
The cytosolic GSTs may also be further subdivided in two major subgroups, namely the S/C-
GSTs and the Y-GSTs.30 Analysis of the sequence identity and structural similarity of the 
cytosolic GSTs combined with knowledge of the enzymatic mechanism of the enzymes has 
revealed that all the cytosolic GSTs bind and activate GSH through one of two ways: either a 
Cys/Ser residue (S/C-GSTs) or a Tyr residue (Y-GSTs). Members of the Y-GSTs include the 
Alpha, Mu, Pi, Sigma and Plasmodium falciparum GSTs whereas the C/S-GSTs are the Beta, 
Omega, Phi, Tau, Theta and Zeta GSTs.  Members belonging to the same major subgroup are 
more closely related to each other than they are to any GST outside of their subgroup. In fact, 
evidence suggests that the Y-GSTs are a later evolutionary offshoot of the S/C-GSTs.30 
 
1.2.2. The structure of cytosolic glutathione S-transferases 
 
Though GSTs of different classes share little sequence similarity (~40%), crystal structures of 
the GST enzymes show that the structural fold of the proteins is highly conserved (Figure 4). 
Cytosolic GSTs have a dimeric quaternary structure (Mr ~ 50 kDa) and exist as obligate homo- 
or heterodimers,31-33 though the subunits will always be from the same class (Figure 5A). Each 
subunit in turn may be subdivided into two distinct domains: Domain 1 or the N-terminal 
domain has a mixed α/β domain, topologically similar to the thioredoxin fold (a mixed β-sheet
6 
 
Figure 3: Nomenclature for cytosolic GSTs as laid out in Mannervik et al. (2005).29 Many of the 
older references used in this study use an out-of-date nomenclature for GSTs, Mannervik et al. (2005)29 
also includes a list of the older nomenclatures and how they should be referenced today. 
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Figure 4: A structural alignment comparison subunits from five classes of Y-GSTs. Despite sharing 
a maximum of forty percent sequence identity, the structural folds of the subunits of Alpha (1K30, 
always coloured black), Mu (1GTU), Pi (16GS), Plasmodium falciparum (3FR6) and Sigma (2WB9) 
class GSTs can be seen to have very similar structural folds. Notice the lack of any comparable structure 
to the α9 of Alpha class GST. This figure was prepared using UCSF Chimera.34 
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Figure 5: The crystal structure of the homodimer hGSTA3-3. (A) Showing a complete GSTA3 subunit in red, the second subunit is divided into domain 1 
(yellow) and domain 2 (blue). The substrate / co-factor GSH and the product Δ4-AD (orange), Tyr9, Arg15 on the active-site loop and its salt-bridge contact 
Glu104 are shown as stick models. The domain interface and the axis of symmetry at the subunit interface are signposted.  This protein fold is indicative of the 
typical GST protein with the exception of the unique α9 of Alpha class GSTs. (B) The substrate / co-factor GSH (yellow) and the product Δ4-AD (orange) are 
shown bound to the G-site (blue) and H-site (red), respectively in the top right corner. The second active site can be seen in the bottom left corner. Image 
generated from the PDB file 2VCV using the program PyMol.35  
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of four β-strands and three α-helices with a folding topology corresponding to βαβαββα), 
domain 2 or the C-terminal domain is entirely α-helical.31 36 
 
Domain 1 of GSTs is always highly conserved and shows high sequence similarity even 
between GST classes.37,38 Domain 2 by contrast shows far greater malleability in its structure 
and sequence and forms the distinguishing feature between most GST isoenzymes.36 One such 
example is the unique α-helix 9 (α9) in domain 2 of the Alpha class GSTs.39,40 
 
1.2.3. The active site 
 
GST dimers contain two active sites (Figure 5B). Each active site is located at the confluence 
of the subunit and domain interfaces of GST.  Each active site, therefore, is composed of 
structural elements of both domains of a subunit and from both subunits of the dimer.31  
Meaning, an active site requires proper domain association and dimerisation for full 
functionality (GSTs are obligate dimers).31,41,42  Nevertheless, each active site of a dimer 
behaves independently of the other.43 
 
Each GST active site may also be further subdivided into two binding sites (Figure 5B): the 
first is the hydrophilic G-site which is responsible for binding GSH, the defining substrate of 
the enzyme, and the second is the adjacent H-site which binds a widely diverse range of 
hydrophobic substrates.32,36 
 
The G-site is highly specific for GSH and this can be explained in how the G-site is formed 
primarily form the highly conserved domain 1, thought to be descended and conserved from 
the single domain (an ancestral thioredoxin fold) protein ancestor of all GSTs.36-38 Nevertheless, 
there are still some noteworthy differences between the classes. The binding of GSH to the G-
site involves a network of polar interactions between GSH and domain 1 of a subunit and two 
salt-bridge interactions between both ends of the GSH tripeptide and two residues (Asp101 and 
Arg131) of domain 2 of the second subunit of the GST enzyme.  The latter interactions are 
not highly conserved however, while both are present in the Alpha class, there is only one 
interaction in the Mu, Pi and Sigma classes and none in the case of the Theta class by way of 
example.31 Additionally, the sulfur atom of GSH forms a close contact with the hydroxyl group 
                                                          
 These residue numbers are based on the consensus sequence of Alpha class GSTs 
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of Tyr9 in the Y-GSTs30 and in the case of the Alpha class of GSTs another close contact with 
the Nε of Arg15.44,45 Both residues are part of the so called active site loop connecting β-strand 
1 with α-helix 1 in domain 1. Similarly, in the case of S/C-GSTs the sulfur atom of GSH will 
either form a hydrogen bond with the hydroxyl group of  Ser13 or it will form a disulfide bond 
with Cys15.30 Since the Alpha class GSTs are the primary concern of this study, it should be 
noted that Arg15 plays a role in stabilising the conformation of the active site loop by forming 
a salt-bridge with Glu104 of α-helix 4 in Alpha class GSTs.39,40,44 
 
The H-site, in contrast, is a far less specific binding site.32 The H-site of each GST isoenzyme 
is capable of binding a wide assortment of hydrophobic substrates with each isoenzyme within 
and across classes having its own unique, sometimes overlapping substrate specificities. The 
H-site is a solvent-exposed hydrophobic pocket that is formed between three sides. The active 
site loop (the loop connecting β-strand 1 with α-helix 1 in domain 1), the C-terminus of helix 
4 and in the case of the Alpha class of GSTs the region immediately prior to and including α-
helix 9 (Met208, Leu213, Ala216, Ala219 Phe220 and Phe222).46   
1.2.4. The catalytic mechanism 
 
GST enzymes perform a vital role in cellular defence against toxic physiological and xenobiotic 
compounds16,32 as well as the harmful compounds created from oxidative stress.47 In all cases, 
the enzyme performs its phase II detoxification14 role by catalysing the conjugation of reduced 
glutathione (GSH) to the toxic compound. The conjugated product is far more soluble than the 
toxic substrate allowing for subsequent excretion by biological pathways such as the 
mercapturate pathway.32,48 
 
The primary means by which GSTs catalyse the above reaction is to lower the energy required 
to deprotonate GSH.49,50 The enzyme accomplishes this by lowering the pKa of GSH after it 
binds the G-site, principally by stabilising the deprotonated anionic GS- form of GSH through 
interactions with either a Tyr, Cys or Ser residue (Section 1.2.1.).30 The nucleophilic GS- anion 
then attacks the electrophilic centre of the hydrophobic substrate bound at the H-site and the 
two substrates are conjugated by nucleophilic substitution. The high cellular concentration of 
GSH (1-10 mM), at least three orders of magnitude higher than its Kd, makes it likely that GSH 
is always the first substrate to bind to the enzyme.31,32 The sequential mechanism above may 
be represented as follows:49-51  
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E + GSH ⇌ E·GS- + H+ ⇌ E·GS-·R-X ⇌ E·GSR·X- ⇌ E + GSR + H·X 
 
where E is the GST enzyme, R-X is the hydrophobic electrophilic substrate, GSH is the reduced 
glutathione, X is the leaving group and GS- is the highly reactive thiolate anion. The reaction 
is hypothesised to pass through a transition state, an analogue of a Meisenheimer complex, 
which is typical of nucleophilic addition reactions.49,52 Kinetic studies indicate the formation 
of the transition state is the rate limiting step. The conjugation of GSH to 2,4- 
dinitrochlorobenzene (CDNB), a reaction often used to assay the detoxifying catalytic 
efficiency of GST enzymes is shown as a specific example (Figure 6).51  
 
The sulfhydryl group of free GSH in an aqueous solution has a pKa of 9.2
53 and upon binding 
to the active site of a Y-GST the pKa is lowered to between 6.2 and 7.1.
45,53,54 As revealed 
previously, the critical residue involved in Alpha class GSTs is Tyr9, which stabilises the 
deprotonated form of GSH by forming a hydrogen bond between the sulfur atom of GSH and 
its own hydroxyl group. It has been revealed, in the case of GSTA1-1, that Tyr9 is not fully 
responsible for lowering the pKa of the GSH sulfhydryl group. The Arg15 residue (conserved 
in the Alpha class) through the positive electrostatic potential of its guanidinium group plays a 
significant role in stabilising the negatively charged thiolate form of GSH.44,45 Indeed, it has 
been shown that the interaction between GSH and the Arg15 residue of GSTA1-1 lowers the 
pKa of the GSH sulfhydryl group further than the interaction between GSH and Tyr9. It has 
been speculated that the role of Arg15 will be the same in GSTA3-3 though it has never been 
experimentally examined.  
1.3. The dual roles of the GST enzymes 
 
It is not unexpected that enzymes of the same protein superfamily would all share similar 
reaction chemistry and common mechanistic pathways.55 Certainly this is the case of the GST 
enzymes which all share phase II detoxification activity. While there are differences in how 
each GST interacts with its substrates, and while GSTs may differ in their substrate specificity 
at their H-sites, each GST nevertheless performs the conjugation of GSH to a hydrophobic 
substrate as described above. More and more, however, researchers are discovering additional 
functions of the GST enzymes.  
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Figure 6: The glutathione S-transferase catalysed nucleophilic aromatic substitution reaction 
(SNAr) of GSH with CDNB to form S-(2,4-dinitrophenyl) glutathione, showing the putative 
transition state.51 
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Able to bind a wide variety of hydrophobic compounds at their H-site, GSTs play an important 
role in ligand transport and intracellular storage of a variety of non-substrate compounds such 
as hormones, metabolites, heme, steroids and drugs.18,56-58  Further, some GSTs play an 
important role in signal transduction pathways by interacting with protein kinases.11,59,60 Of 
interest to this study is that some GSTs have even evolved catalytic promiscuity. That is to say 
that despite a shared structural scaffold and similar reactive functional groups, some GSTs have 
evolved to catalyse distinct chemical reactions.55,61 More precisely, they follow a catalytic 
pathway different to the one indicated by their Enzyme Commission number. There are GSTs 
that are able to catalyse the isomerisation 13-cis-retinoicacid, maleylacetoacetate and, 
particularly of interest to this study, ketosteroids.62 Normally an enzyme responsibly for the 
isomerisation of a ketosteroid would have an EC 5.3.3.1 number. Enzyme plasticity is thought 
to give rise to promiscuous enzymes, the native catalytic activity of an enzyme is typically 
robust towards changes. That is to say point mutations at less well conserved regions of an 
active site often do not significantly diminish the native activity but may result in new 
functions.62-64 Plasticity may also be the result of point mutations outside of the active site 
which may nevertheless result in enzyme repacking and changes in tertiary contacts within the 
protein resulting in structural or more ephemeral conformational dynamic changes at the active 
site that give rise to promiscuous reactions.65 Promiscuous activities are typically slow relative 
to the main native activity; often so slow as to be physiologically irrelevant, and are under 
neutral selective pressure.61,66  However, changes in selective pressures that infer a fitness 
benefit on the promiscuous activity may prompt an evolutionary refinement such that the 
promiscuous activity of the enzyme becomes its new main activity.61,67  
 
An alpha class GST, GSTA3-3, is one of the most important steroid isomerase enzymes in 
humans.10,11  That GSTA3-3 is selectively expressed in the testes, ovaries, adrenal glands and 
placenta argues that its role as a steroid isomerase enzyme has become its primary focus.11 
GSTA3-3 is still able to act as a detoxification enzyme but with reduced efficiency as compared 
to the rest of the Alpha class. Likewise, GSTA3-3 is not the only Alpha class GST that can act 
as a steroid isomerase but it has by far the greatest catalytic efficiency in regard to the reaction 
(see Table 1 for a comparison). In other words, plasticity in the Alpha class GSTs has allowed 
steroid isomerase activity to develop but only in the case of GSTA3-3 has that activity been 
selected for. 
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Table 1: Comparing the specific activities of Alpha class GST enzymes and KSI for the 
substrates CDNB and Δ5-AD 
Enzyme Specific Activity (μmol.min−1.mg−1) 
CDNB Δ5-AD 
GSTA1-1 111 ± 8a 12b 
GSTA2-2 58 ± 4a 0.172a 
GSTA3-3 23 ± 2c 197 ± 15c 
GSTA4-4 7.5d 0.03a 
KSI NA 55000e 
a Pettersson and Mannervik (2001)53 
b Bjornestedt et al. (1995)45 
c Johansson and Mannervik (2001)11 
d Hubatsch et al. (1998)68 
e Hawkinson et al. (1991)69 
NA, not applicable 
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Previous studies have helped to elucidate the nature of how steroid isomerase activity has come 
about in the Alpha class of GSTs. Despite all Alpha class GSTs sharing over 80% sequence 
identity70 there are important point mutations between them. Of particular note in this instance 
is that the H-site residues at positions 10, 12, 111, 208, 216 in the Alpha class GSTs are not 
conserved among GSTA1-1, GSTA2-2 and GSTA3-3 (Table 2).70-72 These five residues 
account for 50% of the H-site. Comparing the crystal structures of the three isoenzymes 
indicated that only the H-site of GSTA3-3 is large enough to be able to accommodate the Δ5-
AD substrate such that is has a favourable orientation in regard to GSH at the G-site for the 
steroid isomerase reaction to be possible (see Figure 3C in Tars et al., 2010).72 GSTA1-1 which 
has the most comparable H-site to GSTA3-3 is able to accommodate both substrates at the 
active site simultaneously but with unfavourable orientations whereas GSTA2-2 by 
comparison is unable to bind both substrates simultaneously. In fact, it has been revealed that 
when five point mutations are made to GSTA2-2 to make its H-site match that of GSTA3-3, 
its steroid isomerase activity rises to be ~80% of GSTA3-3.73 The five mutations uncover the 
potential steroid isomerase activity that exists within all Alpha class GSTs. Plasticity at the H-
site, therefore, gives rise to steroid isomerase activity in the Alpha class GSTs, while the ability 
of the enzyme to bind and interact with GSH at the G-site remains.  
 
It is worth mentioning that detoxification enzymes are among the most substrate and 
catalytically promiscuous enzymes known.74-76 The nature of a detoxification enzyme requires 
that they protect an organism from a wide range of toxic compounds, even from xenobiotics 
foreign to the organism, necessitating broad substrate specificity/ambiguity.75 It is speculated 
that detoxification enzymes are at the limits of substrate promiscuity attainable within the limits 
of a defined protein fold. Evidence has revealed that substrate promiscuity is often the first step 
towards catalytic promiscuity.77-79 This is clearly demonstrated in the above case which 
demonstrated how five point mutations can lead to steroid isomerisation activity in GSTA2-2. 
Similarly, GSTA1-1 can be modified by only two point mutations to have greater catalytic 
activity for the 4-hydroxy-2-nonenal substrate, normally catalysed by GSTA4-4 with two-fold 
greater efficiency.74  This latter case also illustrated that catalytic promiscuity must often be 
balanced against decreased stability. 
 
The Alpha GSTs have far greater substrate promiscuity than other GST enzymes. This is due 
to greater conformational heterogeneity at the active site (specifically the unique and dynamic 
α-helix 9), but also throughout the protein structure.74 In particular, flexibility at the domain  
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Table 2: Differences in the residue makeup of the H-sites of GSTA1-1, GSTA2-2 and 
GSTA3-3 
Enzyme Residue number 
10 12 111 208 216 
GSTA1-1 Phe Ala Val Met Ala 
GSTA2-2 Ser Ile Phe Met Ser 
GSTA3-3 Phe Gly Leu Ala Ala 
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interface around Trp21 was implicated in the broad catalytic range of hGSTA1-1. GSTs, 
therefore, provide an excellent model to study the nature of both substrate and catalytic 
promiscuity. 
 
1.3.1. Isomerisation of Δ5-AD by GSTs 
 
GSTA3-3 uses the same structural scaffold common to all GSTs and more, it uses the same 
reaction machinery. That is to say, GSTA3-3 uses the same functional groups and residues to 
carry out its steroid isomerase reaction, as the Y-GSTs and more specifically the Alpha class 
GSTs use to catalyse their detoxification reactions. Nevertheless, there are important 
differences, perhaps the most obvious being that GSH is not a co-substrate in regard to the 
steroid isomerase reaction but instead acts as a cofactor.40,72  
 
GSTA3-3 has attracted significant interest and research as a major player in steroid 
isomerisation, not only in the Alpha class of GSTs, but as the most efficient steroid 
isomerisation enzyme in humans.11 The products of its steroid isomerisation reactions Δ4-AD 
(the precursor to testosterone) and progesterone are essential to good health, so much so that 
both are included in the WHO Model List of Essential Medicines.  Additionally, GSTA3-3 is 
a potential therapeutic drug target in the treatment of diseases characterised by excessive 
steroid hormone production such as polycystic ovary syndrome, Cushing’s syndrome, 
congenital adrenal hyperplasia and some cancers of the sex organs.80 
 
Yet, the steroid isomerase reaction mechanism of GSTA3-3 has yet to be resolved definitively. 
There are two major competing reaction mechanisms (Figure 7)40,72 at present, each of which 
accounts for some of the observed experimental evidence, but not all. Both proposed 
mechanisms agree that GSH is an important cofactor.  GSH will bind to the G-site (GSH is 
thought to bind the G-site first due to its high cellular concentration of between 1-10 mM in 
the cell) and will assume its deprotonated GS- form which is stabilised by interactions with 
Tyr9.  So far, the enzyme has behaved no differently than it would when performing its 
detoxification reaction. The changes are only evident when a ketosteroid binds to the H-site. 
The GSH in contrast to its previously established role as a nucleophilic attacker, instead acts a 
base catalyst that abstracts a proton from C4 of the Δ5-AD substrate. There is a fine line 
between basicity and nucleophilicity (nucleophiles are weak Lewis bases) indicating that it is  
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Figure 7: The two proposed reaction mechanisms for Δ5-AD isomerisation by hGSTA3-3. In 
Scheme 1, 40 the deprotonated GS- thiolate anion abstracts the carbon 4 proton of Δ5-AD, a water 
molecule acts as a hydrogen bond donor, stabilising the negative charge of the dienolate intermediate 
(a,b). The keto form is regenerated by the transfer of the abstracted proton to carbon 6, by the transfer 
of negative charge via a conjugation system of π-bonds with Tyr9 acting as a proton shuttle (c). More 
recent evidence has found no proof of the proposed stabilising water molecule and it has been proposed 
that GSH plays a dual role of abstracting carbon 4 and stabilising the negative charge of O3 and the 
intermediate.70 In Scheme 2, 72 GS- abstracts a proton from carbon 4 while simultaneously transferring 
it to carbon 6. Bond formation and bond breaking occur simultaneously via a concerted single step 
mechanism, without a dienolate intermediate. In this mechanism, the role of Tyr9 is simply to help 
maintain the lower pKa of GSH.   
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the lack of a proper leaving group in the steroid substrate that prevents the GS- anion from 
acting as a nucleophilic attacker. 
 
At the moment that GS- deprotonates Δ5-AD at C4, the competing reaction mechanisms begin 
to differ. In Scheme 1 (stepwise),40 it was proposed that the reaction is step-wise and proceeds 
via a dienolate intermediate. It was proposed originally that electron delocalisation alone would 
stabilise the intermediate (via a conjugate system of vacant p-orbitals along O-C3-C4-C5-C6), 
but this explanation proved insufficient to explain the observed catalytic rates of GSTA3-3. A 
hypothetical water molecule was posited next that would act as a hydrogen bond donor to the 
carbonyl oxygen to stabilise the intermediate but no evidence of its existence has been 
discovered in crystal structures. Regardless, it was proposed that the intermediate is then 
protonated at C6 resulting in the product Δ4-AD. Originally it was believed that the now 
protonated GSH would act as the proton donor but crystallographic data indicated it was too 
distant from C6 (~5 Å).80 This data combined with experimental evidence that Tyr9 is itself 
deprotonated and reprotonated during the reaction71 led to the conclusion that Tyr9 must act a 
proton shuttle. The hydroxyl group of Tyr9 protonates the intermediate at C6 and is in turn 
reprotonated by GSH. This leads to the deprotonation of GSH again, which after the product 
leaves and is replaced by fresh substrate at the H-site allowing the reaction to proceed again.  
This scheme remains contentious due to there being, as yet, no satisfactory explanation for how 
the intermediate might be stabilised. 
 
In trying to address the shortcomings of the previous reaction mechanism a second reaction 
mechanism was proposed. Scheme 2 (concerted)72 posits that that GSH does not merely act as 
a base catalyst but rather acts as an acid catalyst as well. GSH abstracts a proton from C4 while 
nearly simultaneously transferring it to C6. Bond breaking and bond formation occur via a 
single step concerted mechanism without a stable dienolate intermediate ever forming. Scheme 
2 (concerted) successfully explains away the need for a stable intermediate but it fails to 
account for the distance between GSH and C6 in crystal structures, and evidence that Tyr9 may 
play a role beyond simply stabilising the GS- anion. Additionally, GSH has been shown not to 
be an obligate cofactor, even in the absence of GSH, GSTA3-3 is able to catalyse the 
isomerisation of Δ5-AD to a significant degree, which seems to argue against GSH having such 
a prominent role in the reaction.53 
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1.3.1.1. Stepwise versus concerted reactions 
 
Neither scheme is completely satisfactory and has left several details indeterminate. The critical 
difference between the two reaction schemes is the presence or absence of a stable intermediate 
during the reaction. That is, Scheme 1 proposes a stepwise reaction while Scheme 2 proposes 
a concerted single step mechanism.  
 
Each type of reaction mechanism has its own advantages and disadvantages (Figure 8). For 
example, removing a H atom near the keto group of Δ5-AD results in a negative charge 
imbalance in the steroid.  The charge imbalance, in turn, results in electronic instability and an 
unfavourable high energy species (a transition state).81  In a stepwise reaction, enzymes may 
make use of a variety of stratagems to stabilise the transition state. One approach is to use the 
functional group of a residue of opposite charge to the imbalance to stabilise it.  The reduction 
in instability increases the lifetime of the species and it becomes an intermediate. The 
stabilisation of the intermediate can have many advantages for a catalysed reaction. In the case 
of multiple resonance forms, the enzyme may control the outcome of the reaction by stabilising 
a particular resonance form. Additionally, by completing the reaction over two or more steps, 
rather than one, the reaction can proceed through individual steps whose individual activation 
energies are lower than their sum. Intermediates also allow the enzyme to create kinetic and/or 
thermodynamic barriers which allows for greater control and can prevent reversible reactions.   
 
This is the method used by KSI (EC 5.3.3.1). KSI shares ~43% sequence identity with GSTA3-
3 and catalyses the same steroid isomerisation reaction, though without the use of a cofactor, 
with two orders of magnitude greater efficiency8 (Figure 9; Table 1). After abstracting a proton 
from C4 of Δ5-AD, KSI stabilises the resulting transition state by balancing the negative charge 
of the O3 oxyanion through two hydrogen bonds, C6 is then protonated forming the product. 
Discounting the role of GSH, this is similar to Scheme 1 (stepwise) proposed for GSTA3-3. 
Recall, however, that there is no known means by which GSTA3-3 may stabilise the transition 
state.  
   
An alternative approach, the concerted mechanism,82-84 is when two or more primitive changes 
such as bond-formation and bond-breaking occur within the same elementary reaction. 
Therefore, the reaction occurs through a single step passing through only one transition state, 
without any intermediates.  The advantage of a concerted mechanism is that since the reaction
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Figure 8: Comparing the energy diagrams of a stepwise, concerted and enforced concerted 
mechanism. (A) is a SN1 reaction diagram representative of a stepwise mechanism. (B) is an SN2 
reaction diagram that is representative of a concerted mechanism. Both are nucleophilic substitution 
reactions that involve the removal of a leaving group (X-) and replacing it with a nucleophile (Nuc:-). 
In the SN1 reaction, the leaving group leaves first creating a stable carbocation intermediate which is 
then bound to the nucleophile creating the product. In the SN2 reaction, the leaving group leaves 
simultaneously to the nucleophile binding to the carbocation centre, the reaction has no intermediate 
and passes through a single transition state. Various conditions such as the strength of the nucleophile, 
the solvent (aprotic or protic) and the bulk of the alkyl groups attached to the electrophile will determine 
if the reaction proceeds through an SN1 or SN2 reaction. (C) Energy diagram showing an enforced 
concerted mechanism (II) on the borderline between stepwise (I) and concerted (III) mechanisms. A 
change in reaction conditions can reduce the energy barrier of the second transition state that the 
reaction proceeds immediately from the ‘intermediate’ to the product. This proceeds so quickly that the 
intermediate exists for so short a time that it arguably ceases to exist.  Notice how the ‘intermediate’ no 
longer has a defined energy well between two transition states (the broken line - - -).  
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Figure 9: The catalytic mechanism of KSI. The reaction begins when a proton is abstracted from C4 
of Δ5-AD by Asp38 of KSI. The resulting dienolate intermediate is stabilised by two hydrogen bonds 
formed between the carbonyl oxygen of Δ5-AD Tyr14 and Asp99 (the oxyanion hole). The abstracted 
proton is then transferred to C6 forming the product Δ4-AD. This reaction mechanism is analogous to 
the proposed Scheme1 (stepwise) mechanism for GSTA3-3, the differences are that KSI does not need 
a cofactor and has an oxyanion hole to stabilise the intermediate. This figure is reproduced from Daka 
et al., (2014).85 
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is so rapid no substantial charge imbalance can build and there is no need for stabilisation of 
the transition state.83 Further, if the timing of the two steps is sufficiently synchronous they 
may become energetically coupled, so that the simultaneous progress of the primitive changes 
involves a transition state of lower energy than that for their successive occurrence.83 For 
example, the energy released from bond formation may aid in bond breaking if both primitive 
changes occur simultaneously.83 
 
It may be helpful to clarify the difference between a transition state and an intermediate. A 
transition state lies at a saddle point on potential-energy surface through which a reaction must 
pass on going from reactants to products. It has a fleeting existence and exists for less than the 
time of a bond vibration (~10-13 seconds).82,86 An intermediate is a molecular entity with a 
lifetime appreciably larger than a molecular vibration that is formed from the reactants and 
reacts further to give products.   
1.4. Does the dienolate intermediate exist? 
 
Since the critical difference between the two reaction schemes is the presence or absence of a 
stable dienolate intermediate proof of its existence would be a strong indication that Scheme 1 
(stepwise) is correct.  Conversely, however, lack of proof of an intermediate may not always 
indicate a concerted mechanism.83 
 
Pollack et al. (1989)87 and Zeng et al. (1991)88 have done extensive work in characterising the 
non-catalysed isomerisation of Δ5-AD to Δ4-AD under acidic and basic conditions. The non-
catalysed isomerisation reaction passes through a dienolate intermediate under basic conditions 
and passes through a diene intermediate under acid conditions. Additionally, their work has 
shown that the ideal absorbance wavelength of the diene intermediate is 238 nm (ε13800 
M−1.cm−1) but when the diene is ionised to its dienolate state it becomes 256 nm (ε15000 
M−1.cm−1).  
 
Recently, Daka et al. (2014)85 found evidence of an intermediate during the steroid 
isomerisation reaction. Monitoring the GSTA3-3 catalysed isomerisation of Δ5-AD to Δ4-AD 
at either A238 and A256 they detected an increase in absorbance which subsequently decreased 
as the reaction continues to proceed, suggesting the formation of an intermediate which 
subsequently goes on to form product. Additionally, they note that when equilenin (an analogue 
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of the putative intermediate) is bound to GSTA3-3 it appears to be in its un-ionised form, 
suggesting that the intermediate, at least in the GSTA3-3 catalysed isomerisation reaction, is 
actually a diene85 and not a dienolate as it is in KSI.9  The detection of the intermediate (whether 
a diene or dienolate) strongly suggests Scheme 1 (stepwise). 
 
Alternatively, a Quantum Mechanics/Molecular Mechanics (QM/MM) computational analysis 
of the GSTA3-3 catalysed steroid isomerisation mechanism by Calveresi et al., (2012) agrees 
that Scheme 1 (stepwise) is correct but suggests the reaction (based on the computationally 
predicted energy diagram of the reaction) is actually an enforced concerted mechanism which 
should not have a true intermediate.80 The computational model suggests that GS- will 
deprotonate the C4 of Δ5-AD nearly simultaneously to Tyr9 protonating Δ5-AD at C6 to create 
the product.  Interestingly, the calculated thermodynamics and energy diagrams of this 
computationally predicted model are in strong agreement with the experimentally determined 
values of Daka et al., (2014).  The computationally calculated thermodynamic parameters are 
nearly two-fold greater, because they were based on the dimeric structure of GSTA3-3 and not 
just a single active site.89   
 
These two works, together, strongly suggest that Scheme 1 (stepwise) is correct but still leave 
the nature of the intermediate as contentious.  
1.5. Aim and objectives 
The overriding aim of this study was to further elucidate the steroid isomerisation reaction 
mechanism of hGSTA3-3.  
 
The two major competing reaction mechanisms (Figure 7), as well as more recent proposals, 
have left several details unanswered or controversial: (i) does the reaction proceed through a 
dienolate intermediate and, if so, how is it stabilised? (ii) what is the role of the GSH cofactor? 
(iii) what is the role of Tyr9? (iv) are there any other active site residues important to catalysis? 
Additionally, it needed to be examined what, if any differences, separates GSTA3-3 from the 
rest of the Alpha class? 
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In order to examine these questions, this study sought to examine the enzymatic, structural and 
conformational properties of the wild-type, Y9F, R15L and Y9F/R15L GSTA3-3 enzymes. 
The following general objectives were determined: 
   
• Create plasmids which code for Y9F, R15L and Y9F/R15L hGSTA3-3 
• Express and purify wild-type, Y9F, R15L and Y9F/R15L hGSTA3-3  
• Determine the effects of the mutations on the structure of hGSTA3-3.  
• Determine the effects of the mutations on the stability of hGSTA3-3. 
• Determine the effects of the mutations on the conformational dynamics of hGSTA3-3. 
 
The Y9F mutation was chosen because Tyr9 is highly conserved in GSTs and an important 
catalytic residue in GSTA3-3 which features prominently in the Scheme 1 (stepwise) reaction 
mechanism. The Y9F mutation removes the hydroxyl group of Tyr but otherwise does not 
affect the bulk of the residue. The R15L mutation was selected because Arg15 plays a 
significant role in the GSTA3-3 catalysed steroid isomerisation reaction. Arg15 is a highly 
conserved residue in Alpha GSTs which is important for lowering the pKa of GSH but which 
has not undergone experimental evaluation in GSTA3-3. The R15L mutation was chosen 
because it removes the positive charge of the Arg residue but closely matches the bulk of the 
residue. Moreover, the R15L variant is a common natural substitution found in GST classes 
other than Alpha and has been the mutation of choice in other research works.  As Arg15 is 
part of a salt-bridge it is necessary to examine if the mutation affects the structure, stability or 
conformational dynamics of the enzyme.  
 
To answer the more specific questions, the following objectives were determined: 
 
• Determine if the dienolate intermediate exists 
• Determine if Tyr9 significantly contributes to the transformation of the intermediate 
to product 
 
The experiments by Daka et al. (2014)85 to detect the intermediate during the GSTA3-3 
catalysed steroid isomerisation reaction can prove the existence of the dienolate intermediate 
along the reaction pathway. Additionally, Scheme 1 (stepwise) predicts Tyr9 is the major active 
site residue which protonates the intermediate at C6 to form the product. It was, therefore, 
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hypothesised that Y9F GSTA3-3 might be able to generate the intermediate but there should 
be evidence of the intermediate being converted to product at a decreased rate.  This would 
provide strong evidence that Tyr9 acts a proton shuttle.  
 
• Determine the effect of the mutations on the enzymatic properties of hGSTA3-3 
 
To further investigate the role of the Tyr9 and Arg15 residues as well as the GSH cofactor, an 
extensive investigation into the enzymatic properties of GSTA3-3 was carried out. The role of 
the residues in binding and in lowering the pKa of GSH were examined. Additionally, the 
specific activities of wild-type, Y9F, R15L and Y9F/R15L for the conjugation and steroid 
isomerisation reactions were examined. 
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Chapter 2 
Experimental Procedures 
 
 
2.1. Materials 
 
The codon harmonised nucleic acid sequence encoding wild-type hGSTA3-3 with a N-terminal 
6×His-tag and thrombin cleavage site was designed by Dr I. Achilonu (University of the 
Witwatersrand, South Africa). It was synthesised and sub-cloned into a pET-11a plasmid by 
GenScript Corporation (NJ, USA). The QuikChange II Site-Directed Mutagenesis Kit was 
purchased from Stratagene (La Jolla, CA, USA). Ampicillin and chloramphenicol were 
purchased from Roche Diagnostics (Mannheim, Germany). Inqaba Biotec (Pretoria, South 
Africa) conducted synthesis of the necessary oligonucleotide primers and performed all 
sequencing to confirm the identity of the plasmids. The Escherichia coli JM109 and BL21 
(DE3) pLysS competent cells were obtained from Stratagene (La Jolla, CA, USA). The 
GeneJET™ Plasmid Miniprep Kit was obtained from Inqaba Biotec (Pretoria, South Africa). 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) protein molecular 
weight markers (MWM; SM0431) and isopropyl-β-D-thiogalactoside (IPTG) were obtained 
from Fermentas Life Sciences (St. Leon-Rot, Germany). CDNB, GSH and D2O were obtained 
from Sigma-Aldrich (St. Louis, MO, USA). The steroids, Δ5-androstene-3,17-dione and Δ4-
androstene-3,17-dione, were obtained from Steraloids Inc (Newport, RI). All other reagents 
were of analytical grade. All solutions and media were prepared using distilled water and 
filtered through a 0.45 μm filter unless otherwise stated. 
 
2.2. Preparation of mutant plasmids 
 
The pET-11a plasmid coding for wild-type hGSTA3-3 (provided by Dr I. Achilonu) was 
modified to create three mutant plasmids encoding for Y9F, R15L and Y9F/R15L hGSTA3-3 
according to the protocol of Papworth et al. (1996)90 in conjunction with the QuikChange Site-
                                                          
 Only those methods not covered in detail in the published paper in Chapter 4 are described here. 
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Directed Mutagenesis Kit. First, a reaction mix of 51 μl comprised of 5 μl (10× concentrate) 
reaction buffer, 1 μl (50 ng) double-stranded DNA template (pET-11a plasmid), 1 μl (125 ng) 
forward primer, 1 μl (125 ng) reverse primer, 1 μl dNTP mix, 41 μl milli-Q water and 1 μl (2.5 
U/μl) Pfu DNA polymerase was set up. The reaction mix was subjected to a polymerase chain 
reaction (PCR) (Figure 10). Finally, the parental DNA template was digested with 1 μl (10 
U/μl) DpnI, for one hour at 37 °C and one hour at 20 °C. DpnI targets methylated DNA only 
and, as such, only the parental DNA plasmid produced in a cellular environment was digested. 
Afterwards, the cells were transformed (Section 2.3.) with the remaining plasmids for the 
purposes of producing the variant proteins (Section 2.4.). 
 
Primers, to create each mutant, were designed in accordance with the codon harmonised nucleic 
acid sequence encoding for GSTA3-3 (Figure 11) using Primer-X and analysed for hairpins 
and loops by Gene Runner (V3.01, Hastings Software Inc., NY, USA). The primers are listed 
in Table 3.  The primers to create Y9F and R15L mutant plasmids were applied to wild-type 
encoding pET-11a plasmid. The primer to create Y9F/R15L plasmid was applied to GSTA3-3 
Y9F encoding pET-11a after it was created and expressed in E. coli JM109 cells (Section 2.3.) 
(this step is essential to ensure the base plasmid is made from methylated DNA). 
2.3. Bacterial Transformation 
 
Wild-type GSTA3-3 encoding pET-11a plasmid as well as the final DNA products of the above 
experiment (Section 2.2.) were used to transform JM109 Escherichia coli competent cells. The 
JM109 cell line was used to express and obtain high concentrations of quality plasmid DNA. 
Transformation was carried out by a one-step heat shock method.91 All inoculation and growth 
procedures were conducted with sterilised media, containers and pipette tips using aseptic 
techniques under sterile conditions. Each plasmid (5 μl) was incubated on ice with 50 μl 
Escherichia coli cells which were subsequently heat shocked at 42 °C on a heating block for 
45 s before being transferred back to ice for two minutes. Afterwards, 900 μl SOC expression 
recovery medium (super optimal broth with catabolite repression: 2% (w/v) tryptone, 0.5% 
(w/v) yeast, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 20 mM glucose) was added to each 
preparation, and thereafter incubated at 37 °C for 1 hour on a shaker (250 rpm).  
                                                          
 http://www.bioinformatics.org/primerx/ 
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Figure 10: The polymerase chain reaction protocol used in conjunction with the QuikChange II 
Site-Directed Mutagenesis Kit. The procedure begins with an initialisation step (segment 1) whereby 
the temperature is raised to 95 °C for 180 s to denature the plasmid DNA into single strands. The 
reaction then proceeded to segment 2 which was repeated for 18 cycles, the 3 steps of the cycle are the 
denaturation step (same as segment 1), annealing step (the temperature is lowered just enough for the 
primers to anneal to the now single strands of the DNA plasmid) and elongation step (the temperature 
is raised slightly to promote optimum efficiency of the polymerase enzyme). The procedure ends on a 
long final elongation step (segment 3) to ensure any remaining single-stranded DNA is fully extended. 
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A 
1 
61 
121 
181 
241 
301 
361 
421 
481 
541 
601 
661 
721 
  CATATGGCTA GCATGACTGG TGGACAGCAA ATGGGTATGC ACCATCATCA TCATCATTCT  
TCTGGTCTGG TGCCACGCGG TTCTATGGCA GGGAAGCCCA AGCTTCACTA CTTCAATGGA  
CGGGGCAGAA TGGAGCCCAT CCGGTGGCTC TTGGCTGCAG CTGGAGTGGA GTTTGAAGAG  
AAATTTATAG GATCTGCAGA AGATTTGGGA AAGTTAAGAA ATGATGGGAG TTTGATGTTC  
CAGCAAGTAC CAATGGTTGA GATTGATGGG ATGAAGTTGG TACAGACCAG AGCCATTCTC  
AACTACATTG CCAGCAAATA CAACCTCTAC GGGAAAGACA TAAAGGAGAG AGCCCTAATT  
GATATGTATA CAGAAGGTAT GGCAGATTTG AATGAAATGA TCCTTCTTCT GCCCTTATGT  
CGACCTGAGG AAAAAGATGC CAAGATTGCC TTGATCAAAG AGAAAACAAA AAGTCGCTAT  
TTCCCTGCCT TCGAAAAAGT GTTACAGAGC CATGGACAAG ACTACCTTGT TGGCAACAAG  
CTGAGCCGGG CTGACATTAG CCTGGTGGAA CTTCTCTACT ATGTGGAAGA GCTTGACTCC  
AGCCTTATCT CCAACTTCCC TCTGCTGAAG GCCCTGAAAA CCAGAATCAG CAACCTGCCC  
ACGGTGAAGA AGTTTCTACA GCCTGGCAGC CCAAGGAAGC CTCCCGCAGA TGCAAAAGCT  
TTAGAAGAAG CCAGAAAGAT TTTCAGGTTT TAAGGATCC 
 
B 
 
Figure 11: The codon harmonised nucleic acid sequence encoding wild-type hGSTA3-3 with a N-
terminal 6×His-tag and thrombin cleavage site. (A) The DNA sequence was codon harmonised to 
maximise protein expression in Escherichia coli cells. (B) The translated protein sequence. The 
thrombin cleavage site is highlighted in yellow, the thrombin enzyme will cleave the protein between 
the arginine and glycine residues marked with asterisks.  
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Table 3: Oligonucleotide primer sequences used for site-directed mutagenesis 
Protein 
name 
 
Fwd/Rev 
primer 
Primer sequence 
 
Codon 
change 
hGSTA3-3 
Y9F 
 
Fw 
 
5' CCCAAGCTTCACTTCTTCAATGGACGGG 3' TAC→ TTC  
Rev 
 
5' CCCGTCCATTGAAGAAGTGAAGCTTGGG 3' GTA→GAA 
hGSTA3-3 
R15L 
 
Fw 
 
5' CAATGGACGGGGCTTAATGGAGCCCATCC 3' AGA→TTA 
Rev 
 
5' GGATGGGCTCCATTAAGCCCCGTCCATTG 3' TCT→TAA 
hGSTA3-3 
Y9F/R15L 
 
Fw 
 
5' CAATGGACGGGGCTTAATGGAGCCCATCC 3' AGA→TTA 
Rev 
 
5' GGATGGGCTCCATTAAGCCCCGTCCATTG 3' TCT→TAA 
The position of the desired altered nucleic acid sequence is highlighted in yellow. 
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Successful transformants were selected by plating the Escherichia coli cells on lysogeny broth 
(LB) agar [1% (w/v) tryptone, 0.5% (w/v) yeast, 0.5% (w/v) NaCl] containing 100 μg.ml-
1ampicillin. The plates were then incubated overnight (16-24 h). Only cells containing the pET-
11a plasmid would have ampicillin resistance and be able to grow on the agar plate. 
 
Plasmid DNA was extracted from the cells using the GeneJET™ plasmid miniprep kit 
(Fermentas, St. Leon-Rot, Germany) via the protocol of the kit.92,93 The purified plasmid DNA 
was used in PCR (Section 2.2.), sequencing confirmation (Inqaba Biotec; Pretoria, South 
Africa) and transformation (via the same method already described) of BL21 (DE3) pLysS 
Escherichia coli competent cells for use in protein expression. When selecting for successful 
transformants of the BL21 (DE3) pLysS Escherichia coli competent cells, 30 μg.ml-1 
chloramphenicol was added to the agar plates because the pLysS plasmid also encodes for 
chloramphenicol resistance.  
 
2.4. Heterologous protein expression and purification 
 
The heterologous over-expression of wild-type and mutant GSTA1-1 encoding pET-11a 
plasmids was performed in BL21(DE3) pLysS Escherichia coli cells (Lucigen, Middleton, WI, 
USA) according to the method described by Daka et al. (2014).85  BL21(DE3) pLysS 
Escherichia coli cells are suitable for the expression of non-toxic heterologous genes. The λ 
DE3 lysogen carries the gene for T7 RNA polymerase under control of the lacUV5 promoter, 
required for transcription of the pET-11a plasmid. The pLysS plasmid is important because it 
encodes T7 lysozyme which reduces basal polymerase transcription allowing the plasmid to 
become established and also provides chloramphenicol resistance to the cell.94  
 
Since T7 RNA polymerase gene of DE3 lysogen is under lacUV5 control its expression may 
be induced by the addition of IPTG.95  IPTG binds to the lacI repressor, inhibiting it and 
allowing transcription via the lacZ promoter. Unlike the natural inducer of this gene (lactose), 
IPTG cannot be broken down in the cell, resulting in the genes becoming irreversibly over-
expressed which, in turn, leads to the production of large amounts of T7 RNA polymerase. T7 
RNA polymerase is extremely promoter specific and will transcribe only DNA that is 
downstream of a T7 promoter. In this case, the gene of interest on the pET-11a plasmid, and is 
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so prolific that most resources of a cell are converted to target gene expression. The desired 
gene product can comprise more than 50% of total cell protein a few hours after induction.  
  
All inoculation and growth procedures described below were conducted in the presence of 100 
μg.ml-1 ampicillin and 30 μg.ml-1 chloramphenicol, to create an environment hospitable only 
to the BL21 cells of interest. In addition, all procedures were carried out in Erlenmeyer flasks 
that were five times greater in volume than that of the culture to ensure adequate aeration during 
growth. 
 
2.4.1. Induction studies 
 
Induction studies were performed to determine if any changes needed to be made to the 
protocol of Daka et al. (2014)85 to find the optimal conditions for the expression of wild-type, 
Y9F, R15L and Y9F/R15L GSTA3-3. Cultures of Escherichia coli BL21 (DE3) pLysS cells, 
already transformed with either wild-type, Y9F and R15L encoding pET-11a, in 2×YT media 
[1.6% (w/v) tryptone, 1% (w/v) yeast extract, 0.5% (w/v) NaCl] were incubated at 20 or 37 °C 
and 250 rpm until the start of the late-log phase (OD600 = 0.6). IPTG was then added to cultures 
at final concentrations of 0-1 mM to induce over-expression of the pET-11a plasmids. After 
induction, the cultures were left to incubate between 4-16 h at 20 or 37 °C and 250 rpm. Cells 
were then harvested from equal volumes of cell culture by centrifugation at 5000 g for 20 min 
at 10 °C. The pellets were re-suspended in equilibration buffer (10 mM sodium phosphate, 1 
mM ethylenediaminetetraacetic acid (EDTA), 0.02% sodium azide, pH 7.45), 0.02 mg.ml-1 
DNAse, 0.02 mg/ml lysozyme and 2 mM MgCl2 were added to further promote cell lysis and 
break down DNA, before lysis by sonication at 4 °C. The lysate was centrifuged at 13 000 g at 
4 °C for 30 minutes and the supernatant and pellet collected. Samples of the supernatant and 
pellet were assessed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) according to the method of Laemmli (1970)96 (Section 2.5.). 
 
Subsequent over-expression procedures were conducted under those conditions which proved 
to be optimal.  
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2.4.2. Protein purification 
 
The wild-type, Y9F, R15L and Y9F/R15L GSTA3-3 proteins were purified from their 
respective supernatants by immobilised metal affinity chromatography using a HisTrap FF 5 
ml column (GE Healthcare Life Sciences, Uppsala, Sweden) charged with nickel according to 
the protocol of the column. The respective supernatants were diluted 1:1 with binding buffer 
(20 mM Tris-HCl, 200 mM NaCl, pH 7.4) and filtered through a 0.2 μm syringe filter to remove 
any large aggregates. The diluted supernatant was then loaded onto to the HisTrap column pre-
equilibrated with 10 column volumes of binding buffer using an AKTA automated 
chromatographic system. The AKTA system monitored the eluate constantly via the on-board 
Jasco V-550 UV/Vis spectrometer and the column was washed with more binding buffer until 
an A280 reading of 0.000 was reached, indicating that weakly interacting, unbound, protein had 
already been eluted from the column.  The column was then washed with elution buffer (20 
mM Tris-HCl buffer containing 0.5 M imidazole at pH7.4) in a continuous gradient from 0-
100% over 150 ml to elute bound protein. The eluent was collected in 2 ml fractions and 
spectroscopically assessed at 280 nm, again by the on-board spectrometer, for the presence of 
protein. To mitigate the risk of cross-contamination each protein was purified through use of 
its own HisTrap column.  
 
Fractions containing pure protein, as assessed by SDS-PAGE, were pooled and concentrated 
on ice to a volume of 10 ml by ultra-filtration using a membrane with a molecular weight cut-
off of 10 kDa. 
 
2.4.3. Thrombin cleavage 
 
After purification by IMAC, the protein underwent thrombin cleavage to remove the 6×His-
tag and a second purification step to isolate the now cleaved protein. Purified wild-type, Y9F, 
R15L and Y9F/R15L protein were dialysed against thrombin cleavage buffer (20 mM Tris-
HCl, 200 mM NaCl, 5 mM CaCl2 at pH 8). After dialysis, 10 μl of a 1 U/μl stock of thrombin 
was adder per ml of protein solution and cleavage was allowed to proceed overnight (~12 h) at 
room temperature.  
 
After the thrombin cleavage protocol was completed, the reaction mix was purified through a 
HisTrap FF and HiTrap benzamidine FF column (GE Healthcare Life Sciences, Uppsala, 
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Sweden) connected in series. Both columns were pre-equilibrated with binding buffer. The 
HisTrap column removes the cleaved 6×His-tag and the HiTrap benzamidine column removes 
thrombin from solution. Cleaved GSTA3-3 passed through both columns without binding and 
was collected in the eluate. The purity of thrombin cleaved protein was confirmed using 12% 
SDS-PAGE.  
 
Pure, cleaved wild-type, Y9F, R15L and Y9F/R15L GSTA3-3 protein was dialysed against 
storage buffer (20 mM sodium phosphate buffer containing 1 mM EDTA and 0.02% (w/v) 
sodium azide at pH 7.45), concentrated to 10 ml and aliquoted in 1 ml volumes into cryogenic 
tubes, snap-frozen in liquid nitrogen and stored at -80 °C until use. 
 
2.5. SDS-PAGE 
 
Cell lysate obtained during induction studies and protein fractions obtained during the 
purification procedures were assessed by SDS-PAGE (Laemmli, 1970).96 Cell lysate samples 
(10 μl) and protein samples (10 μl) were diluted two-fold with sample buffer [10% (w/v) 
glycerol, 2% (w/v) SDS, 5% (w/v) β-mercaptoethanol, 0.05% (w/v) bromophenol blue]. The 
samples were then heated at 95 °C for 5 minutes to ensure all protein was fully denatured and 
bound to SDS. SDS-PAGE is an electrophoretic technique wherein molecules are separated 
according to their electrophoretic mobility as they travel through a polyacrylamide matrix by 
the generation of an electric potential difference between either ends of the gel. Denaturing the 
protein gives them all a uniform shape and SDS is an anionic surfactant that binds to the protein 
and masks their natural charge. The result is that the electrophoretic mobility of the protein is 
a result of their size only, making the technique useful to determine the purity and size of a 
protein, which goes a long way in allowing the identity of a protein to be inferred.97 
 
The samples were loaded into the wells of 12% (w/v) acrylamide/bis-acrylamide gels which 
were hand cast from a TGX™ FastCast™ Acrylamide kit (BioRad, California, U.S.).  The gels 
were immersed in electrode buffer [1% (w/v) SDS, 0.192 M glycine and 0.025 M Tris, pH 8.5.] 
and electrophoresed at 180 V with discontinuous amperage for ~45 min using a Bio-Rad 
electrophoresis system (Bio-Rad, California, U.S.). A molecular weight marker (Fermentas 
Life Sciences, (cat. no.: SM0431), Ontario, Canada) was electrophoresed alongside the protein 
samples. The marker was a mixture of seven proteins: β-galactosidase (116 kDa), bovine serum 
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albumin (66.2 kDa), ovalbumin (45 kDa), lactate dehydrogenase (35 kDa), restriction 
endonuclease Bsp98I (25 kDa), β-lactoglobulin (18.4 kDa) and lysozyme (14.4 kDa). After 
electrophoresis, the gels were left in staining solution [2% (w/v) Coomassie Blue R250 staining 
solution containing 13.5% (v/v) glacial acetic acid and 18.75% (v/v) ethanol] for an hour and 
then de-stained with de-staining solution [40% (v/v) methanol and 10% (v/v) glacial acetic 
acid] until the background was clear to visualise the results. 
 
Purity is indicated by a single band on the gel and identity of the proteins can be inferred by 
the distance the protein band travelled alongside a control lane containing a known pure 
solution of the protein, or protein markers of known molecular weight. Pure wild-type or any 
of the mutant GSTA3-3 proteins should correspond to a molecular weight of ~27 kDa 
uncleaved and 25.4 kDa post cleavage. 
2.6. Protein concentration determination 
 
The concentration of wild-type, Y9F, R15L and Y9F/R15L GSTA3-3 was determined 
spectrophotometrically using a Jasco V-630 UV-VIS spectrophotometer (Jasco Inc., Tokyo, 
Japan) and by applying the Beer-Lambert law:  
 
                     A = εcl       (1) 
  
where A is the absorbance of the sample, ε is the molar extinction coefficient (M-1.cm-1), c is 
the concentration of the sample in solution (M) and l is the path length of the light passing 
through the solution (cm). An experimentally determined subunit molar extinction coefficient 
of 23900 M−1 cm−1 was used for wild-type GSTA3-3 and all three variant proteins.11 The 
concentrations were determined by fitting a linear regression to five or more points from a 
serial dilution. All readings were corrected for the signal caused by the buffer alone. In the 
absence of an experimentally determined molar extinction coefficient, it may be calculated by 
using the formula described by Perkins (1986):98 
 
ε = 5550∑Trp + 1340∑Tyr +150∑Cys   (2) 
 
The formula indicates that wild-type GSTA3-3 should have a subunit molar extinction 
coefficient of 17760 M−1.cm−1 (only 74.3% of the experimentally determined value). 
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Nevertheless, it highlights that replacement of a Tyr residue with a Phe residue in the Y9F and 
Y9F/R15L variants may alter their determined subunit molar extinction coefficients. The 
accuracy of the calculated protein concentrations was, therefore, checked with the Bradford 
assay. 
 
The concentration of stock solutions of GSH were also determined spectrophotometrically 
through use of Ellman’s reagent to quantify the number of thiol groups in the stock 
solutions.99,100  
2.6.1. Bradford assay 
 
The Bradford assay is a colourimetric protein assay, based on the absorbance shift Coomassie 
Brilliant Blue G-250 dye experiences upon binding to Arg and other aromatic residues of a 
protein under acidic conditions; specifically, the absorbance properties of the dye undergo a 
hypsochromic shift.101 This allows the protein concentration to be measured as a function of 
absorbance at 595 nm. Samples of both wild-type and variant protein shown to have an equal 
A280 were diluted 100 times, reacted with 100 μl of Bradford reagent (BioRad, California, USA) 
and measured at A595. 
 
While the R15L and Y9F/R15L variants have one less Arg residue than the wild-type, it is not 
expected that the loss of a single Arg residue would significantly affect the ability of the 
Bradford assay to act as a check. 
 
2.7. Detecting the dienolate intermediate  
 
The ideal absorbance wavelengths for the diene or dienolate intermediate generated during the 
conversion of Δ5-AD to Δ4-AD, in the absence of the enzyme, were found to be 238 and 256 
nm respectively.87,88  An enzyme-catalysed reaction was carried out using 10 μM Δ5-AD and 2 
mM GSH (personal communication with J. Daka85) in the presence of 1 μM GSTA3-3 and 
monitored by absorbance spectroscopy (A238, A256) in an attempt to detect the dienolate 
intermediate.85 
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2.8. Urea unfolding 
2.8.1. Reversibility of unfolding 
 
In order to calculate the change in Gibbs free energy during protein unfolding it must first be 
demonstrated that a state of equilibrium exists between the folded and unfolded states of the 
protein. This, in turn, requires the protein to be able to unfold reversibly and, further, that the 
protein refolds along the same path that it unfolds (i.e. there is no hysteresis effect).  
 
All enzymes were confirmed to unfold reversibly, monitored by circular dichroism (CD), as 
described previously.102 Samples of 20 μM unfolded wild-type, Y9F, R15L and Y9F/R15L 
protein, incubated in GST storage buffer with 8 M urea for 1 h at 20 °C, was achieved by a 10-
fold dilution of each sample with GST storage buffer [20 mM sodium phosphate buffer 
containing 1 mM EDTA and 0.02% (w/v) sodium azide at pH 7.45] for 1 h at 20 °C. The 
refolded state of the protein was assessed using far-UV CD at 222 nm. All spectra were buffer 
corrected. The spectra were normalised by calculating the mean residue ellipticity, [Ѳ] 
(deg.cm2.dmol-1), using the following equation:103 
 
[Ѳ] =
𝟏𝟎𝟎× Ѳ  
𝑪𝒏𝒍   
                                                               (3) 
 
where, Ѳ is the measured ellipticity signal in mdeg, C is the protein concentration in mM, n is 
the total number of residues in the protein chain, and l is the path length in cm. The amount of 
protein that was able to return to its native state was calculated by the comparison of the spectra 
of refolded protein with spectra of a control sample of 2 μM protein in 0.8 M urea, either wild-
type, Y9F, R15L and Y9F/R15L variant as appropriate. The method to prove that the protein 
refolded along the same pathway on which it unfolds is described in Section 2.8.2. 
 
2.8.2. Urea-induced equilibrium unfolding/refolding 
 
Equilibrium unfolding studies were  also performed as described previously.104  Samples of 
2 µM protein in 20 mM sodium phosphate buffer (pH 7.4), 1 mM EDTA, 0.02% (w/v) sodium 
azide and 0-8 M urea were used. Structural changes were monitored by far-UV CD at 222 nm 
and by fluorescence using excitation wavelengths of 280 and 295 nm with fluorescence 
emission recorded at 328 nm and 330 nm, respectively. The latter measurement is an excellent 
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local probe of the stability around the lone Trp21 residue of the protein subunits, which is near 
the active site. Rayleigh scatter plots of fluorescence (Ex340; Em340) were performed to monitor 
any protein aggregation. The experiment was performed in triplicate. Data were fitted and 
analysed using SigmaPlot v13.0 (Systat Software Inc; Chicago, IL, USA; Section 2.8.3.).  
 
Refolding of the wild-type, Y9F, R15L and Y9F/R15L GSTA3-3 was also conducted over the 
same range of urea concentrations to prove equilibrium and the absence of hysteresis (Section 
2.8.1.). Solutions of 20 μM wild-type, Y9F, R15L and Y9F/R15L GSTA3-3 protein in GST 
storage buffer with 8 M urea was diluted, with stocks of 10 M urea and GST storage buffer, as 
appropriate, to a protein concentration of 2 μM in various concentrations of urea and left to 
incubate for 1 hour at 20 ºC. The resultant unfolding and refolding curves were compared to 
identify whether the unfolding of the wild-type and variant hGSTA3-3 enzymes does indeed 
take place under equilibrium conditions.  
 
2.8.3. Data fitting 
 
All unfolding and refolding data obtained for the proteins were analysed according to a two-
state unfolding process for a dimeric protein. 
 
During a reversible two-state unfolding of a dimeric protein equilibrium is reached between 
the native (N) and the unfolded species (U): 
 
N2 ⇌ 2U       (4) 
 
Furthermore, during a two-state unfolding transition, only the unfolded and native states are 
present at significant concentrations.105 Hence, for a two-state mechanism: 
 
𝒇𝑵 + 𝒇𝑼 = 𝟏       (5) 
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where fN is the fraction of folded or native protein and fU is the fraction of unfolded protein. 
The recorded spectroscopic signal at any point during the unfolding of the samples is therefore 
in fact the sum of the signal of both species: 
 
    𝒚𝟎 = 𝒚𝑵𝒇𝑵 + 𝒚𝑼𝒇𝑼      (6) 
 
where y0 is the signal obtained for the respective spectroscopic probe, fN represents the fraction 
of folded protein, and fU represents fraction unfolded protein. Further yN represents the y value 
for the folded state and can be extrapolated from the linear pre-transition region of the 
unfolding data, while yU represents the y value for the unfolded state and can be extrapolated 
from the linear post-transition region of the unfolding data (Figure 12). 
 
By combining equations 5 and 6, the fraction of unfolded protein can be obtained: 
 
 𝒇𝒖  =
(𝐲𝐍 – 𝐲)
(𝐲𝐍 – 𝐲𝐔)
           (7) 
  
The equilibrium constant for the unfolding reaction (Keq) is: 
 
    𝑲𝐞𝐪 =
[𝒇𝑼]
𝟐
[𝒇𝑵]
      (8) 
 
The total protein concentration, Pt, expressed in terms of the monomeric species is: 
 
𝑷𝒕 = 𝟐𝑵𝟐 + 𝑼       (9) 
 
and the fraction of native dimeric species is: 
 
 𝑭𝑵 = 𝟏 − 𝑭𝑼       (10) 
 
where: 
 
 𝑭𝑼 =
[𝑼]
𝑷𝒕
       (11) 
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Figure 12: Representation of a typical two-state urea denaturation curve. The pre-transition region 
(plot of YN) where the protein remains folded, post transition region (plot of YU) where the protein is 
fully unfolded and the transition region where the protein is a state of equilibrium between the folded 
and unfolded states as a function of urea concentration are shown. Image adapted from Shirley 
(1995).106    
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Combining these equations and solving for FU in terms of the equilibrium constant Keq and Pt, 
one obtains the following equation: 
 
    𝑭𝑼 =
√𝑲𝒆𝒒
𝟐+𝟖𝑲𝒆𝒒𝑷𝒕−𝑲𝒆𝒒
𝟒𝑷𝒕
     (12) 
 
Rearranging equation 7 yields the equation used for fitting the denaturation transitions: 
 
 𝒚𝟎 = 𝒚𝑵(𝟏 − 𝒇𝑼) + 𝒚𝑼(𝒇𝒖)     (13) 
 
Substituting equation 13 allows the keq of unfolding to be calculated and hence Δ𝐺°according 
to the equation: 
 
 𝚫𝑮° = −𝑹𝑻𝐥𝐧𝑲𝒆𝒒       (14) 
 
where ΔG° is the free energy of unfolding, R is the gas constant and T is temperature in Kelvin. 
In order to determine ΔG(H2O) it is assumed that according to the linear free-energy model ΔG° 
has a linear dependence on denaturant concentration [D] for all urea concentrations (Tanford, 
1968, 1970). Therefore: 
 
 𝚫𝑮° = 𝚫𝑮(𝑯𝟐𝟎) + 𝐦[𝐃]     (15) 
 
where ΔG(H2O) represents the free energy difference between the folded and unfolded states in 
the absence of denaturant, m is the m-value for the dependence of free energy on denaturant 
concentration (calculated from the linear equation 15 which has the formulae y = mx+c) which 
is also an indicator of co-operativity and can be related to the change in solvent-accessible 
surface area (ΔSASA),107,108 and [D] is the denaturant concentration. 
 
The equilibrium unfolding data obtained was fitted with these equations using SigmaPlot 
version 13.0 (Systat Software Inc; Chicago, IL, USA) and the parameters ΔG(H2O) and the m-
value were obtained.  
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Chapter 3 
Results 
 
 
3.1. Sequencing  
 
The sequencing results of the open reading frame (ORF) for wild-type GSTA3-3 encoding 
pET-11a plasmid matched exactly to the sequence ordered by Dr I. Achilonu.  The sequencing 
of the mutant plasmids indicated the desired mutations were successfully inserted and that no 
unwanted mutations had occurred (Figure 13).  
3.2. Over expression and purification 
3.2.1. Induction studies 
 
Induction studies were performed to optimise the expression of Y9F and R15L GSTA3-3. The 
results of the induction studies were examined by SDS-PAGE (Figure 14). It was found in both 
cases that the optimum induction conditions were the same as that for the wild-type. Namely, 
cultures were induced by adding IPTG to a final concentration of 1 mM and incubated at 37 °C 
for ~16 h before cells were harvested. Similarly, like the wild-type, both Y9F and R15L 
GSTA3-3 was soluble in the supernatant fraction of the lysate. In light of this result no 
induction studies were performed on the Y9F/R15L GSTA3-3 mutant and it too was expressed 
under the same conditions. 
3.2.2. Purification 
Purified cleaved wild-type and mutant GSTA3-3 was obtained from cell lysate through a two-
step process (Section 2.4.), first 6×His-tag wild-type and mutant GSTA3-3 was purified from 
cell lysate via IMAC using a HisTrap FF column (Figure 15). In the second step, this purified 
protein underwent thrombin cleavage to remove the 6×His-tag and then went through a second 
purification step to isolate wild-type and mutant GSTA3-3 from the cleaved tag and thrombin 
(Figure 16). 
                                                          
 Only those results not covered in sufficient detail in the published paper in Chapter 4 are reported here. 
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Figure 13: Extracts of the sequencing results showing successful site-directed mutagenesis creating plasmids which code for Y9F, R15L and Y9F/R15L 
GSTA3-3.   The successful incorporation of the primer sequences is shown in boxes, the position and successful incorporation of the desired mutations are 
indicated by arrows.  No unwanted mutations were incorporated into the sequences.  
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Figure 14: Expression patterns of Y9F GSTA3-3 at 20 °C and 37 °C and under induction from 
various concentrations of IPTG.  The results indicate that Y9F GSTA3-3 has higher levels of 
expression in the presence of IPTG, though at concentrations between 0.2-1.0 mM the change in 
expression levels appears minimal. Significant amounts of Y9F GSTA3-3 were present in the 
supernatant with significant levels of Y9F GSTA3-3 present in the pellet only after 16 h. This data is 
also representative of the results seen for R15L GSTA3-3 (not shown).  Optimal expression of Y9F 
GSTA3-3 occurred after 16 hours at 37 °C in the presence of 1 mM IPTG.  
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Figure 15: Elution profile of cell lysate containing wild-type GSTA3-3 during IMAC purification and proof of purity. (A) Elution was monitored at A280 
(black), the position of the collected elute fractions suspected of containing pure wild-type GSTA3-3 are marked. Protein release was triggered by increasing 
concertation of Imidazole (Buffer B; Red). (B) SDS-PAGE analysis of the selected fractions. The analysis indicated pure protein of ~25 kDa which corresponds 
to the expected mass of 27 kDa for pure GSTA3-3. Similar results were obtained for the Y9F, R15L and Y9F/R15L. 
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Figure 16: Showing purified wild-type, Y9F, R15L and Y9F/R15L GSTA3-3 post 6×His-tag 
cleavage.  Lane 1 is 6×His-tagged wild-type GSTA3-3 and lanes 2-5 are wild-type, Y9F, R15L and 
Y9F/R15L GSTA3-3 (with the 6×His-tag removed), respectively. It can clearly be seen that the cleaved 
proteins travel further down the gel which is typical for proteins of a lower molecular weight. Cleavage 
of the 6×His-tag results in the removal of ~1.5 kDa. 
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SDS-PAGE was used to analyse the molecular mass and purity of wild-type, Y9F, R15L and 
Y9F/R15L GSTA3-3.  After final purification, all proteins were judged to be pure as each 
protein showed as only a single band on SDS-PAGE gels.  The molecular weight of the proteins 
was calculated by comparing the distances the GST proteins migrated in comparison to the set 
of known standards that migrated under the same conditions, was ~26 kDa (Figure 15). This 
corresponds to the expected value of 27 kDa. 
3.2.3. Protein concentration determination  
The concentration of wild-type and mutant GSTA3-3 was determined at 280 nm using the 
protein subunit molar extinction coefficient of 23900 M-1.cm-1. The Y9F point mutation was 
confirmed by the Bradford assay to not have any significant effect in altering the extinction co-
efficient of the protein (Table 4).  
 
The wild-type enzyme was purified from one litre of bacterial culture, yielding ~26 mg of 
purified protein. Whereas, one litre of bacterial culture yielded ~63, ~34 and ~49 mg of Y9F, 
R15L and Y9F/R15L GSTA3-3, respectively.   This indicates that none of the mutations 
resulted in lowering the protein yield, suggesting that they do not significantly affect protein 
expression, folding and stability. 
3.3. Detecting the dienolate intermediate 
The presence or absence of an intermediate during the GSTA3-3 catalysed steroid 
isomerisation reaction has significant implications for determining the proper catalytic 
mechanism employed by the enzyme. Recently Daka et al. (2014)85 reported for the first time, 
the detection of an intermediate, via absorbance spectroscopy, during the GSTA3-3 catalysed 
steroid isomerisation reaction. However, the results of Daka et al. (2014)85 could not be 
reproduced in the current study. No intermediate was detected following their protocol with 
wild-type or Y9F GSTA3-3. This was true whether the detection of the intermediate was 
followed at 238 or 256 nm (Section 2.7.). Attempts to reproduce their results with varying 
concentrations of enzyme and Δ5-AD also failed (Figure 17). These findings also made it 
impossible to investigate the importance of Tyr9 in converting the intermediate to product as 
hoped (Section 1.5.).  
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Table 4: Comparing the accuracy of the experimentally determined extinction co-efficient 
for GSTA3-3 for each of the variant proteins. 
Protein Concentration 
determined by 
absorbance (µM) 
Absorbance of Bradford 
dye (arbitrary units) 
Similarity to wild-type 
(%) 
Wild-Type 2 0.1385 100 
Y9F 2 0.1379 99 
R15L 2 0.1339 96.6 
Y9F/R15L 2 0.1352 97.6 
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Figure 17: Attempts to detect the dienolate intermediate during GSTA3-3 catalysed steroid 
isomerisation by absorbance spectroscopy at A238 and A256. If an intermediate was formed during 
the catalysed reaction, there would be an initial rise in the A238 or A256 followed by a subsequent decline 
as the intermediate was transformed into product.  This is not the case in any of the reactions shown 
above where no intermediate was detected.  
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3.4. Conformational stability of wild-type, Y9F, R15L and 
Y9F/R15L GSTA3-3  
 
3.4.1. Reversibility of urea-induced unfolding 
 
The recovery of unfolded wild-type, Y9F, R15L and Y9F/R15L GSTA3-3 to its native, folded, 
state was established by far-UV CD ([Ѳ]222). In each case, after refolding (Section 2.8.1.), wild-
type, Y9F, R15L and Y9F/R15L GSTA3-3 showed > 95% recovery (Figure 18). Additionally, 
it was established that the proteins refold reversibly without any hysteresis effect (Section 
2.8.2.), the proteins refolded along the same pathway they unfold (Figure 18). 
 
The data indicate that wild-type, Y9F, R15L and Y9F/R15L GSTA3-3 establish a state of 
equilibrium between their native and unfolded states in the presence of urea. Thus, the 
unfolding pathways of wild-type, Y9F, R15L and Y9F/R15L GSTA3-3 were analysed using 
thermodynamic principles to determine their conformational stabilities.  
 
3.4.2. Urea-induced equilibrium unfolding 
 
The urea-induced unfolding curves for wild-type, Y9F, R15L and Y9F/R15L GSTA3-3 were 
determined by far-UV CD (Figure 19) and fluorescence spectroscopy (Figure 20).  In each case 
the unfolding curves are sigmoidal and monophasic, indicative of a highly co-operative and 
two-state unfolding curve.109 Therefore, the unfolding curves as monitored by the probes of 
CD and fluorescence were fitted using a two-state model:  
 
N2 → 2U 
 
The free energy change in the absence of denaturant (ΔGH2O), the dependence of free energy 
on denaturant concentration (m-value) and the midpoint of the unfolding transition (Cm) were 
calculated using SigmaPlot V13.0. The thermodynamic parameters are summarised in Tables 
5 (far-UV CD) and 6 (fluorescence spectroscopy).  The majority of the helical structure of 
GSTA3-3 is located in domain 2, whilst the lone tryptophan residue is located in domain 1. CD 
ellipticity is, therefore, primarily a probe of domain 2 unfolding/refolding, while selectively 
excited tryptophan fluorescence reports on the unfolding/refolding around Trp21, a highly 
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Figure 18:  Reversibility of unfolding of wild-type GSTA3-3 monitored by far-UV CD. Overlay of 
an unfolding curve (red) with a refolding curve (green) of wild-type GSTA3-3. Similar data were 
obtained for Y9F, R15L and Y9F/R15L GSTA3-3. 
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Figure 19: Urea-induced equilibrium unfolding of wild-type and mutant GSTA3-3 enzymes as 
monitored by circular dichroism at 220 nm. The wild-type (●), Y9F (♦) and Y9F/R15L (▲) GSTA3-
3 concentration was 2 μM in 20 mM phosphate buffer, pH 7.4, containing 0.1 mM EDTA, and 0.02% 
(w/v) sodium azide. The points are the average of three replicates and error bars showing the standard 
deviation are shown. In each case, the R2 value was > 0.95 and the p-value was < 0.0001 with a 5% 
confidence interval.  
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Figure 20: Urea-induced equilibrium unfolding of wild-type and mutant GSTA3-3 enzymes monitored by fluorescence spectroscopy. (A) represents the 
global unfolding of the enzyme monitored by excitation at 280 nm, (B) represents the unfolding around Trp21 located near the active site as monitored by 
excitation at 295 nm. The wild-type (●), Y9F (♦), R15L (■) and Y9F/R15L (▲) GSTA3-3 concentration was 2 μM in 20 mM phosphate buffer, pH 7.4, 
containing 0.1 mM EDTA, and 0.02% (w/v) sodium azide. The points are the average of three replicates and error bars showing the standard deviation are 
shown. In each case, the R2 value was > 0.95 and the p-value was < 0.0001 with a 5% confidence interval. 
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Table 5: Thermodynamic parameters of two-state equilibrium unfolding for wild-type, 
Y9F, R15L and Y9F/R15L as monitored by circular dichroism  
Far – UV CD  
Wild-type Y9F Y9F/R15L 
ΔG(H2O) (kcal.mol−1) 
 
22.6 (±0.05) 23.2 (±1.88) 21.8 (±1.62) 
m-value 
(kcal.mol−1.M-1 
urea) 
 
3.6 (±0.03) 3.8 (±0.42) 3.5 (±0.38) 
Cm (M urea) 
 
4.2 4.2 4.2 
R2 
 
0.96 0.99 0.99 
 
 
 
Table 6:  Thermodynamic parameters of two-state equilibrium unfolding for wild-type, 
Y9F, R15L and Y9F/R15L as monitored by fluorescence  
Intrinsic fluorescence 
 at 280 nm 
Intrinsic fluorescence  
at 295 nm  
Wild-
type 
Y9F Y9F/R15L Wild-
type 
Y9F R15L Y9F/R15L 
ΔG(H2O) 
(kcal.mol−1) 
 
22.9 
(±2.48) 
21.9 
(±0.60) 
21.6 
(±2.33) 
23.1 
(±0.01) 
22.0 
(±0.23) 
21.9 
(±0.12) 
12.6 
(±1.08) 
m-value  
(kJ.mol−1.M-
1 urea) 
 
3.7 
(±0.58) 
3.5 
(±0.12) 
3.5  
(±0.54) 
3.8 
(±0.08) 
3.5 
(±0.02) 
3.5 
(±0.06) 
1.2  
(±0.22) 
Cm (M urea) 
 
4.2 4.2 4.2 4.2 4.2 4.2 4.5 
R2 0.97 0.96 0.95 0.95 0.99 0.94 0.99 
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conserved residue located near the active site that forms part of an inter-domain lock-and-key 
motif.42 
 
Neither the Y9F nor Y9F/R15L mutations had any effect on the unfolding of domain 2 of 
GSTA3-3 (ellipticity at 222 nm) (Table 5).  Similarly, neither mutation affected the global 
unfolding of the enzyme as monitored by fluorescence (excitation 280 nm) (Table 6).  Since 
the wild-type, Y9F and Y9F/R15L mutations had such similar unfolding properties it was 
unnecessary to examine the R15L mutation.  However, when unfolding was monitored through 
the selective excitation of Trp21 it was seen that while neither mutation alone affected the 
stability of the enzymes, the double mutation caused a decrease in stability (excitation 295 nm) 
(Table 6).  Additionally, the lower m-value could indicate the possibility of intermediates along 
the unfolding path becoming more significantly populated. 
 
The stability of GSTA3-3 closely matches that of GSTA1-1 and the effects of the Y9F and 
R15L mutations are the same as they had on GSTA1-1 as well.44 The data strongly suggest that 
neither Tyr9 nor Arg15 are required for structure or stability of the Alpha class GSTs. In the 
case of Arg15, this result is perhaps surprising as it indicates that the Arg15-Glu104 salt-bridge 
has no significant structural or stabilising role.  
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The effects of mutating Tyr9 and Arg15 on the structure, stability, 
conformational dynamics and mechanism of GSTA3-3 
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In this publication, the effects of Y9F, R15L and Y9F/R15L mutations on GSTA3-3 were 
determined. Data indicate that neither the structure, stability nor conformational dynamics of 
GSTA3-3 are affected. Results from this study show that Arg15 is critical to proper catalytic 
function of the GSTA3-3, and as important as the Tyr9 residue.  
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Supplementary Figures:  
 
 
Figure S1: Far-UV circular dichroism spectra of wild-type and mutant GSTA3-3 
enzymes. Spectra were collected using samples of 2 μM wild-type (_ _ _), Y9F (_____), R15L 
(_ ._) and Y9F/R15L (__ __) GSTA3-3 protein in 20 mM phosphate buffer containing 1 mM 
EDTA and 0.02% (w/v) sodium azide, pH 7.4. The near perfectly overlapping spectra indicate 
that all the proteins have similar secondary structure. 
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Figure S2: Fluorescence emission spectra of wild-type and mutant GSTA3-3 enzymes. 
Spectra were collected using 2 μM wild-type (_ _ _), Y9F (_____), R15L (_ ._) and Y9F/R15L (__ 
__) GSTA3-3 protein in 20 mM phosphate buffer containing 1 mM EDTA and 0.02% (w/v) 
sodium azide, pH 7.5. Excitation at 280 nm (A) and 295 nm (B). The near perfectly overlapping 
spectra indicate that all the proteins have similar tertiary structure. 
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Figure S3: Urea-induced equilibrium unfolding of wild-type and mutant GSTA3-3 
enzymes as monitored by circular dichroism at 220 nm. The wild-type (●), Y9F (♦) and 
Y9F/R15L (▲) GSTA3-3 concentration was 2 μM in 20 mM phosphate buffer, pH 7.4, 
containing 0.1 mM EDTA, and 0.02% (w/v) sodium azide. The points are the average of three 
replicates and error bars showing the standard deviation are shown. 
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Figure S4: Urea-induced equilibrium unfolding of wild-type and mutant GSTA3-3 
enzymes monitored by fluorescence spectroscopy. The unfolding of the enzyme was 
monitored by excitation at 280 nm with excitation measured at 330 nm. The wild-type (●), Y9F 
(♦) and Y9F/R15L (▲) GSTA3-3 concentration was 2 μM in 20 mM phosphate buffer, pH 7.4, 
containing 0.1 mM EDTA, and 0.02% (w/v) sodium azide. The points are the average of three 
replicates and error bars showing the standard deviation are shown. 
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Figure S5: The Y9F/R15L double mutation has no change on the conformational 
flexibility of GSTA3-3 in the presence of GSH. The percentage differences in deuteration 
between wild-type and Y9F/R15L GSTA3-3 in the presence of GSH after 90 s are mapped 
onto the structure of dimeric GSTA3-3 (PDB entry 1TDI), calculated as the percentage of 
deuteration (Y9F/R15L) minus the percentage of deuteration (wild-type). Red coloring 
indicates that the level of deuterium exchange is higher for the mutant protein, while blue 
coloring indicates that the level of deuterium exchange is higher for the reduced protein. 
Helices and β-Sheets are labelled, and the positions of the Tyr9 residue, the Arg15-Glu104 
salt-bridge and Trp21 are indicated. 
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Figure S6: A representative calorimetric profile of the titration of GSTA3-3 with GSH. (A) 
Raw isothermal calorimetric titration curve of GSH binding to wild-type GSTA3-3 at 20 °C in 
20 mM sodium phosphate buffer, pH 6.5, containing 0.1 M NaCl, 1 mM EDTA, and 0.02% 
(w/v) sodium azide. Protein concentration was 0.05 mM monomer and the GSH stock 
concentration was 2 mM. (B) Binding isotherm of integrated data in (A) corrected for heats of 
dilution. The solid line through the data represents the best fit obtained using NanoAnalyze 
software. 
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Figure S7: GSH thiolate formation expressed as a function of pH in the presence and 
absence of GSTA3-3 enzymes. Free GSH (▲), GSH bound to wild-type (●), Y9F (♦) and 
R15L (■) GSTA3-3 are shown. 
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Figure S8: Specific activity of wild-type and mutant GSTA3-3 using the GSH-CDNB 
conjugation assay. The conjugation of CDNB to GSH by enzyme catalysis of wild-type (●), 
Y9F (♦) and R15L (■) GSTA3-3 was monitored by measuring the A340 of the formed product 
1-(S-glutathionyl)-2, 4-dinitrobenzene (ε340 = 9600 M-1.cm-1). The reaction was performed in 
0.1 M sodium phosphate buffer, pH 6.5, containing 1 mM EDTA and 0.02% (w/v) sodium 
azide in the presence of 1 mM GSH and 1 mM CDNB. The assay was corrected for the non-
enzymatic reaction rate. The specific activity of each enzyme is the slope of the linear 
regression plots. The points are the average of three replicates and error bars showing the 
standard deviation are shown. 
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Figure S9: Specific activity of wild-type and mutant GSTA3-3 using the Δ5-AD steroid 
isomerase assay. The steroid isomerization of Δ5-AD to Δ4-AD as catalyzed by wild-type (●), 
Y9F (♦) and R15L (■) GSTA3-3 was monitored by measuring the A248 of the formed product 
Δ4-AD (ε248 = 16300 M-1.cm-1). The reaction was performed in 0.1 M sodium phosphate buffer, 
pH 8.0, containing 1 mM EDTA and 0.02% (w/v) sodium azide in the presence of 1 mM GSH 
and 0.1 mM Δ5-AD. The specific activity of each enzyme is the slope of the linear regression 
plots. The points are the average of three replicates and error bars showing the standard 
deviation are shown. 
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Figure S10: The reaction rate for the steroid isomerization of Δ5-androstene-3-17-dione 
to Δ4-androstene-3-17-dione, catalyzed by 1.5 nM of R15L GSTA3-3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
77 
 
 
Chapter 5 
Discussion and Conclusions 
 
 
5.1. Structure, stability and conformational dynamics of GSTA3-3  
The structure and stability of GSTA3-3 closely matches that of GSTA1-1, as expected for two 
proteins which share > 80% sequence identity (Section 3.4.; Chapter 4).110 Additionally, neither 
the Y9F nor the R15L mutations, singly or together, seem to affect the structure, stability or 
conformational dynamics of the protein (Section 3.4.; Chapter 4).110 The data indicates, 
therefore that the Arg15-Glu104 salt-bridge is neither important to structure, stability nor the 
conformational dynamics of the protein. It is likely that, similar to the case of GSTA1-1, the 
R15L mutation would create a cavity that is filled with water molecules that satisfy the 
hydrogen bonding requirements of Glu104.44 Since the Arg15-Glu104 salt-bridge is unique to 
the Alpha class of GSTs, it is not surprising that the salt-bridge is not critical to protein stability. 
 
However, though there were no changes in the unfolding pathways for the Y9F and Y9F/R15L 
(and by implication R15l) mutants as monitored by far-UV CD and fluorescence spectroscopy 
(Ex280) there were significant differences in the calculated stability and m-value for the 
Y9F/R15L mutant when monitoring unfolding via excitation of Trp21 (Ex295) (Section 3.4.). 
In particular, the lower m-value could indicate the possibility of intermediates along the 
unfolding path becoming more significantly populated. Monitoring unfolding via Trp21 
fluorescence, itself part of an important domain-domain lock-and-key motif near the active site, 
is particularly more sensitive to changes near the active site than the other techniques. 
Indicating that while global unfolding has remained unchanged, the local stability in the region 
around Trp21 (and the active-site) is affected by the Y9F/R15L mutation. It is likely that the 
loss of the interaction between the hydroxyl group of Tyr9 and the backbone of Arg15, which 
can also be maintained between Tyr9 and Leu1544 is responsible for the change in the 
Y9F/R15L double mutant. 
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Based on the slight increase in conformational dynamics at the active site of Y9F/R15L 
GSTA3-3 it may be that the salt-bridge does help to maintain a specific conformation that 
promotes catalytic efficiency, but this would need to be investigated through mutation of 
Glu104. 
 
5.2. Binding and activation of GSH 
Lowering the pKa of GSH is the principal means by which the GSTA3-3 enzyme catalyses both 
its conjugation and steroid isomerisation reactions. Previous studies have consistently reported 
that GSTA3-3 reduced the pKa of GSH further than GSTA1-1 (Chapter 4 - Table 4).
110 This 
may have accounted for some of the differences in the catalytic efficiency of the enzymes. The 
findings of this study, however, show closely matching values between GSTA1-1 and GSTA3-
3, discounting this possibility. This work does show that Arg15 lowers the pKa of GSH further 
than Tyr9, similar to its role in GSTA1-1. 
 
There is, however, a clear and significant difference between the binding affinities of the Alpha 
class GSTs for GSH (Chapter 4 - Table 3).110 GSTA3-3 has a ten-fold greater affinity for GSH 
as compared to GSTA1-1. Since the reaction rates of both the conjugation and steroid 
isomerisation reactions are not close to the diffusion controlled limit, an enhanced affinity for 
GSH could account for some of the differences in catalytic efficiencies between the enzymes. 
The greater affinity for GSH is likely as a result of the larger than typical active site of GSTA3-
3 (Chapter 4).110  
 
5.3. Catalytic activity of GSTA3-3 
The data is clear that the Y9F and R15L mutations singly or combined have a deleterious effect 
on the enzymes catalytic activity (Chapter 4 - Table 5).110 Since neither mutation significantly 
alters the structure, stability or conformational dynamics of the enzyme, however, the 
mutations affect the catalytic activity of the enzyme they must do so solely through the way 
they interact with the substrates.  
 
Both the Y9F and R15L mutations result in comparable decreases in the catalytic activity of 
the steroid isomerisation reaction of GSTA3-3. This is despite the fact that evidence shows that 
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the Arg15 residue is more important for lowering the pKa of GSH (Chapter 4 - Table 4)
110, the 
crux by which the enzyme catalyses the reaction. This argues that Tyr9 may play an additional 
role in the enzyme other than simply lowering the pKa of GSH. This finding is in strong 
agreement with Scheme 1 (stepwise; Figure 7) which argues that Tyr9 also acts as a proton 
shuttle. 
 
5.4. Role of Arg15 
The R15L mutation despite breaking the Arg15-Glu104 salt-bridge did not significantly alter 
the structure, stability or conformational dynamics of GSTA3-3 (chapter 4)110. This indicates 
that the highly conserved Arg15 residue (in the Alpha class) is an important catalytic residue 
based on how it interacts with substrates. Arg15 has long been suspected to be an important 
catalytic residue, specifically in regard to lowering the pKa of GSH, inferred from the role it 
plays GSTA1-1.  Indeed, this is the case with the Arg15 residue in GSTA3-3 lowering the pKa 
of GSH further than even Tyr9 which is considered the primary catalytic residue of Alpha class 
GSTs.  
 
The R15L mutation has been investigated in GSTA3-3 for the first time. This study, however, 
has shown evidence that the R15L GSTA3-3 enzyme shows a rapid decline in its reaction rate 
as compared to either wild-type or Y9F GSTA3-3 (Chapter 4 - Figure 5).110 This decline in the 
reaction rate is probably due to an increased susceptibility of R15L to product inhibition. 
Alternatively, it could be because there is a greater energy barrier to release the product. 
Multiple substrates of GST have shown product release to be their rate limiting step.111 
Previous experiments have indicated that the GSTA3-3 enzyme has an approximately equal 
affinity for the substrate Δ5-AD and the product Δ4-AD11 and any change to this delicate 
balance could, therefore, have significant effects on catalytic activity.  Computational studies 
have predicted that Arg15 is the most important residue in the GSTA3-3 active site for 
stabilising the initial binding of the reactants GSH and Δ5-AD at the active site,80 lending 
credence to this idea. 
 
There is indeed a growing amount of evidence that suggests Arg15 is part of an electron-sharing 
network conserved in all GSTs (there is evidence of the network in Alpha, Delta, Mu, Omega, 
Pi, Sigma, Tau and Theta GSTs).111,112 Although the residues which make up this electron-
sharing network are not conserved in the primary sequences of GSTs the presence of the 
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network can be mapped to the same region in all GSTs.  This further supports the idea that 
Arg15 is not important for structural or stability reasons but is instead integral because of the 
charge of its side group. Indeed, experiments have previously determined that the charge of 
Arg15 is more catalytically significant than its bulk.111 The conservation of this electron-
sharing network which nevertheless demonstrates plasticity in its make-up may be indicative 
of the robust nature of GSTs against point mutations which may nonetheless lead to novel 
functions. After all, the Arg15 residue is specific to Alpha class GSTs and integral to its proper 
function. 
 
5.5. The dienolate intermediate  
 The possible existence of a stable dienolate intermediate has long been a matter of speculation 
and controversy. Recently,  Daka et al., (2014)85 and Calvaresi et al., (2012), have published 
similar energy diagrams for their proposed reaction mechanisms of GSTA3-3 steroid 
isomerisation reaction (Figure 21).80,85  Both papers have argued, based on their energy 
diagrams, that the reaction mechanism of GSTA3-3 consist of two phases: first the C4 of Δ5-
AD is deprotonated by the GSH thiolate sulfur and subsequently the hydroxyl proton of Tyr9 
is transferred to C6 creating the Δ4-AD product. Both groups argue that the first step is rate 
limiting and that the second step proceeds so quickly that the reaction proceeds via an enforced-
concerted mechanism. In the energy diagrams of both studies it can be seen that there is no true 
energy well which would normally correspond to a true intermediate (Figure 8C and 21). Even 
so, Daka et al. (2014)85 reported to have detected a stable intermediate using absorbance 
spectroscopy, a finding that argues against a concerted mechanism.   In light of the inability of 
this study to detect an intermediate, the argument for a concerted mechanism,80,85 and the 
absence of any dienolate intermediate on the reactions computed potential surface,80 it is clear 
that further investigation is needed to clarify whether a stabilised dienolate intermediate, as 
opposed to just a transition state, can truly be detected. 
 
The existence or absence of the dienolate intermediate has important ramifications both for 
solving the reaction mechanism and for drug discovery.  It should be noted that ketosteroid 
isomerase (KSI) (EC 5.3.3.1), a close analogue enzyme that catalyses the same reaction, does 
stabilise the dienolate intermediate during its reaction mechanism and possesses a catalytic 
efficiency three orders of magnitude greater than GSTA3-3.8,69 Indeed, KSI possesses a 
reaction rate that closely approaches the diffusion-controlled limit. If GSTA3-3 stabilises the  
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Figure 21: The reaction pathway for the isomerisation of Δ5–AD by hGSTA3-3 as proposed by 
Daka et al. (2014).85 Δ5–AD (1) is deprotonated by GS- creating a charge imbalance that gives rise to a 
transition state (3). The transition state is stabilised by changes in orbital hybridisation and slight 
structural rearrangements to form the dienolate intermediate (4). Lastly, the intermediate is protonated 
at C6 by Tyr9 as it passes through a second transition state (5) and gives rise to the product Δ4–AD (7). 
Notice the poorly defined energy well for the intermediate (4), the energy barrier between the 
intermediate and the second transition state (5) is only 0.4 kcal.mol-1.  In the computationally predicted 
energy diagram this energy barrier is even lower and only 0.1 kcal.mol-1.80 Such poorly defined energy 
wells are indicative of enforced concerted mechanisms (Compare Figure 8C)
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dienolate intermediate during the reaction, why do the two enzymes have such vastly different 
reaction rates. Indeed, when the residues that stabilise the intermediate in KSI are mutated, the 
specific activity of KSI drops to closely match that of GSTA3-3.113,114 
 
KSI possesses a clear oxyanion hole at its active site that stabilises the negative charge of O3 
(Figure 9) with no comparable structure in the active site of GSTA3-3. How the GSTA3-3 
enzyme could stabilise the dienolate intermediate is not clear. Of the many possibilities 
proposed, the only hypothesis, yet to be disproven, argues that the GSH cofactor plays a double 
role: the thiolate anion of GSH (GS-) acts as a Bronsted base catalyst to deprotonate C4, while 
the main chain amide of the glycine residue of GSH forms a hydrogen bond stabilising the 
negative charge that forms on O3.70 This view is supported by kinetic studies which show that 
the kcat decreases 30-fold and the KM for Δ5-AD increases from 45 to 310 μM.53,71 Such a change 
in KM,  however, has been calculated to contribute to binding energy only 1 kcal.mol
-1, 
indicating that the contribution of the GSH-glycine main chain hydrogen bond with the O3 
atom contributes very little to the kinetic process.85  
 
The nature and existence of the dienolate intermediate, therefore, remains contentious. The 
seemingly conflicting account of an enforced concerted mechanism, that may have a detectable 
intermediate, requires further consideration. Hypothetically, it is possible for a reaction to 
proceed by both a concerted and stepwise mechanism which coexist simultaneously.84 Two 
kinds of circumstances have been proposed under which this could happen. In the first, a 
stepwise and enforced concerted mechanism could coexist when the individual steps of the 
reaction are separated in space and one step occurs by the diffusion controlled reaction of an 
intermediate. The reaction under these circumstances could occur by two separate pathways, 
in which the first step occurs either in the absence (stepwise) or presence (concerted) of the 
final reactant or catalysts.  This is unlikely to be the case in regard to the GSTA3-3 catalysed 
reaction as the intermediate is formed already bound to the final reactant/catalysts (the enzyme 
itself).  In the second circumstance, the different requirement for the concerted and stepwise 
mechanism can facilitate their coexistence if the barriers for the two mechanisms are not very 
different, i.e. the reaction will proceed through an intermediate if it can.  Under these 
circumstances the stepwise mechanism would normally be too unfavourable for this pathway 
to make a significant contribution to the observed reaction rate.115 
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The manner in how the intermediate was detected also requires examination.  The ideal 
wavelengths for the detection of the diene or dienolate intermediate are 238 and 256 nm, 
respectively.87,88 Both wavelengths are within 10 nm or less of the ideal wavelength to detect 
the product (248 nm). Further, the wavelength for the diene intermediate is also only 1 nm 
away from the ideal wavelength to detect the deprotonation of GSH to the thiolate anion GS- 
(239 nm).49 Since the catalytic mechanism predicts that during each reaction GSH will become 
deprotonated to GS-  and then will be reprotonated during the formation of product, it can be 
assumed that both the formation of GS-   and product will interfere with the measured 
absorbance at 238 and 256 nm.  Additionally, the turnover number (kcat) of the GSTA3-3 
isomerisation reaction has been calculated at 7585 and 230111 s-1 at the extreme ends meaning 
that a molecule of product is formed at each active site of GSTA3-3 every 4.5-13 ms. The 
detection limit of traditional absorbance spectroscopy techniques is a few milliseconds. The 
intermediate in question could easily exist for a period of time lower than this detection limit 
because it is not the rate limiting step of the reaction;70,80,85 especially in the case of an enforced 
concerted mechanism.  The contradictory findings of a stable intermediate alongside a 
proposed concerted mechanism is clearly unsatisfactory, and further examination is needed 
solve the matter definitively. 
 
5.6. Conclusion / Mechanistic implications  
Y9F and R15L GSTA3-3 have comparable specific activities in respect to the steroid 
isomerisation reaction, despite the fact that the R15L mutation results in a higher pKa for bound 
GSH. This is a strong indication that Tyr9 plays a role beyond that of just maintaining the pKa 
of GSH. This matches the expectations of mechanism Scheme 1 (stepwise; Figure 7) for the 
steroid isomerisation reaction in which Tyr9 also acts as a proton shuttle.  Additionally, this 
study found no evidence of a dienolate intermediate during the steroid isomerisation reaction, 
nor any compelling theories as to how such an intermediate could be stabilised by GSTA3-3. 
All the experimental evidence in this study agrees with the reaction scheme proposed by the 
computational model of Calveresi et al. (2012)80, whereby the reaction proceeds through a 
concerted single step mechanism. The thiolate anion of GSH (GS-) abstracts the C4 proton 
almost simultaneously to the C6 being protonated by the Tyr9 hydroxyl group. Tyr9 is then 
protonated by GSH in turn which resets the enzyme to its original starting conformation and 
the reaction may proceed again with fresh substrate. This is, in fact, the same model proposed 
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by Daka et al. (2014)85 who detected the intermediate. Given that concerted mechanisms (even 
enforced concerted mechanisms) should not have detectable intermediates the inability of this 
study to detect the intermediate is perhaps unsurprising. All the findings of this study are, 
therefore, in strong agreement with the idea that the Scheme 1 (stepwise) reaction mechanism 
is correct and that the two steps in the reaction proceed via an enforced concerted mechanism.  
 
Finally, for the first time in GSTA3-3, the Arg15 residue has been shown to be crucial to the 
steroid reaction mechanism. It not only acts to lower the pKa of GSH (as expected) but also 
seems to play a crucial role in aiding the enzyme in selecting the reactant (Δ5-AD) over the 
product (Δ4-AD). In the R15L GSTA3-3 variant, the enzyme suffers from a rapidly declining 
reaction rate likely due to greater susceptibility to product inhibition. 
 
GSTA3-3 has attracted significant interest and research as a potential therapeutic drug target 
in the treatment of diseases characterized by excessive steroid hormone production such as 
polycystic ovary syndrome, Cushing's syndrome, congenital adrenal hyperplasia and some 
cancers of the sex organs. Rational drug design would be greatly aided by a thorough 
understanding of the reaction mechanism of GSTA3-3. Though the existence or lack thereof of 
an intermediate during the GSTA3-3 catalysed steroid isomerisation reaction must remain 
contentious for now, hopefully this research has contributed to a more thorough understanding 
of the reaction mechanism.  
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